INDEX

Volume Nineteen—January through December 1985

DRUG INTELLIGENCE AND CLINICAL PHARMACY

JANUARY	Pages 1-80	JULY/AUGUST	Pages 505-616
FEBRUARY	Pages 81-160	SEPTEMBER	Pages 617-696
MARCH	Pages 161-240	OCTOBER	Pages 697-792
APRIL	Pages 241-332	NOVEMBER	Pages 793-880
MAY	Pages 333-412	DECEMBER	Pages 881-976
JUNE	Pages 413-504		

A

Abate, Marie A. (author) Monooctanoin use for Gallstone Dissolution (FF) 708
Abdelfathah, E. (author) Plasma Protein Binding of Methotrexate and 7-Hydroxymethotrexate (ab) 456
Abood, Richard R. (coauthor) see **Brushwood, David B.**, 62
Abraham, Paul A. (author) Efficacy of Once-Daily Terazosin for Essential Hypertension (ab) 454; (coauthor) see **Haistenson, Charles E.**, 455; (coauthor) see **Helm, Karen L.**, 455; (coauthor) see **Matzke, Gary R.**, 455
Abrahamson, Martin (coauthor) see **Cersosimo, Robert J.**, 118
Abramov, A.L. (coauthor) see **Tishler, M.**, 377
Abroms, Israel F. (coauthor) see **Hays, Dennis P.**, 429
Abstracts see **American College of Clinical Pharmacy**
Acebutolol, compared with atenolol, hypertension (CTF) 775; compared with propranolol (CTF) 490; hypertension (CTF) 490
Acetaminophen, hepatotoxicity (CTF) 603; overdose, children (TC) 911
Acetohydroxamic acid, adverse reactions (DSP) 535; evaluation (DSP) 534
Acetylsalicylic acid, see also **Aspirin;** enteric-coated, bioavailability, metabolism (ab) 468
Acquired immune deficiency syndrome, sulfamethoxazole pharmacokinetics (ab) 453
Acyclovir, adverse reactions (FF) 522; continuous infusion (ab) 466; cytomegalovirus (CTF) 67; disseminated varicella (CTF) 603; evaluation (FF) 518; herpes encephalitis (CTF) 227; herpes simplex labialis (CTF) 952; herpes simplex, varicella zoster (CTF) 603; herpes zoster (CTF) 67, 405; oral therapy (FF) 518; peritoneal dialysis (ab) 453; pharmacokinetics (FF) 519; viral shedding (CTF) 866
Adderly, J. (coauthor) see **Steinberg, Irving**, 464
Affrime, Melton B. (coauthor) see **Yost, Richard L.**, 463
AIDS see **Acquired immune deficiency syndrome**
Albuterol, asthma, compared with bitolterol (CTF) 603; congestive heart failure (CTF) 685
Alcohol, fetal alcohol syndrome (CTF) 953; isopropyl, umbilical cord separation (CTF) 776
Alexander, Bruce (coauthor) see **True, Bev Lorraine**, 825
Alexander, Michael R. (author) book review, 403
Alldredge, Brian K. (author) Medical Treatment for Antibiotic Colitis (DIAS) 28
Allin, D. (coauthor) see **MacCosbe, Paul E.**, 446
Allison, T.B. (coauthor) see **Comstock, Thomas J.**, 465
Allopurinol, hepatitis (CR) 431
Alonso, Alberto Gomez (coauthor) see **Barbero, Julita Rodriguez**, 394
Alprazolam, compared with amitriptyline (CTF) 491; compared with doxepin (CTF) 491; depression (CTF) 491; dosing regimen, psychomotor effects, kinetics (ab) 450; stuttering (CTF) 867; withdrawal syndrome (CTF) 491
Alprostadil, rest angina (CTF) 324
Alum, radiation-induced hemorrhage (CTF) 491
Amantadine, enuresis (CTF) 227; myoclonic seizures (CTF) 686; overdose (CTF) 152
Ameer, Barbara (author) A Rapid, Sensitive High Performance Liquid Chromatography Assay of Dipyridamole with Application to Serum Level Monitoring and Dosage Form Analysis (ab) 457
American College of Clinical Pharmacy, abstracts, index, 470; meeting papers, 445; **awards,** fellowship, 9, president's, 779, research institute, 779, therapeutic frontiers lecture, 778; **editorial,** An Official Journal for the American College of Clinical Pharmacy, 920; **fellows,** induction, 779; **meeting, 1985 annual,** abstracts, 445, call for papers, 59, highlights, 777, pharmacy industry forum, 779, president's speech, 868, program announcement, 59, 148, 198, 258, 358, 482, therapeutic frontiers lecture award, 778; **meeting, 1986 annual,** call for papers, 722, 865, 906, program announcement, 739; **news,** annual meeting highlights, 777, fellows inducted, 779, In Pursuit of Clinical Pharmacy Excellence, president's speech, 868; **officers and regents,** installation, 779; **regional therapeutic symposium,** 117; **research institute** awards, 779; **seminar announcements,** with University of Pittsburgh, 61, 117, 198; **therapeutic frontiers lecture,** 1985 award, 778
Amikacin, cancer patients (CTF) 151; compared with cefoperazone (CTF) 602
Amiloride, chlorpropamide interaction (CTF) 152; hydrochlorothiazide, nephrogenic diabetes insipidus (CTF) 602
Amino acids, nutritional support (A) 106
Aminoglycosides, Bayesian vs. weighted least squares, pediatrics (ab) 466; concentrations, pediatrics (ab) 462; cost, cystic fibrosis outpatients (RPR) 52; dosing (L) 396; gram-negative pneumonia (CTF) 227; monitoring, neonates (DIAS) 908; nephrotoxicity evaluation (ab) 451; pharmacokinetics, assay-dependent differences (ab) 464; ultrafiltration (ab) 459
Aminophylline, graft survival (CTF) 228; pefloxacin interaction (L) 945
Amiodarone, death (CTF) 152; epidermal necrolysis (CTF) 953; left ventricular dysfunction (ab) 446; pharmacokinetics (ab) 463; theophylline pharmacokinetics (ab) 454
Amitriptyline, compared with alprazolam (CTF) 491
Amoxapine, tardive dyskinesia (CR) 548
Amoxicillin, clavulanic acid, review (TC) 475; gonococcal urethritis (CTF) 866; potassium clavulanate, adverse reactions (FF) 418, compared with cefaclor, otitis media (CTF) 776, evaluation (FF) 415, pharmacokinetics (FF) 416
D-amphetamine, breast milk levels (CTF) 227
Amphotericin B, bladder irrigations (DIAS) 299; chemoradiation fever (CTF) 151; nephrotoxicity (DIAS) 25; phlebitis (RPR) 436
Ampicillin, chloramphenicol, compared with cefotaxime, bacterial meningitis (CTF) 953
Amrinone, chronic heart failure (CTF) 151
An Opinion, Barone, Joseph A., and Colaizzi, John L., Critical Evaluation of Thioridazine Bioequivalence, 847; **Brushwood, David B.,** A Third Class of Drugs: An Overview, 62; **DuKart, Gary, Iatropoulos, Michael J.,** and **Yacobi, Avraham,** Comment on Mitoxantrone, 216; **Elenbaas, Robert M.,** Definition of Clinical Pharmacy as a Specialty in Clinical Practice, 149
Analgesia, patient-controlled, pentazocine (ab) 457
Anandan, J.V. (coauthor) see **Zarowitz, Barbara J.M.** (ab) 459
Anderson, D. (coauthor) see **Matzke, Gary R.**, 455
Anderson, Donald A. (coauthor) see **Marquardt, Eric D.**, 840
Anderson, Phillip O. (author) Comment: Ceforanide Half-Life (L) 588; (author) Serum Sickness with Cefaclor (DIAS) 186
Anergy, skin testing (DIAS) 300
Anesthesia, local (DIAS) 663
Angaran, David M. (coauthor) see **Bailie, George R.**, 468
Angelopulos, Chris M. (coauthor) see **Green, Laurence**, 427
Announcements, Academy of Pharmaceutical Sciences, 1985 National Meeting, 614; American College of Clinical Pharmacy, Controversies in Cardiovascular Medicine Regional Therapeutic Symposium, 117, Institute, 198, meeting, 1985 annual, call for papers, 59, meeting, 1986 annual, call for papers, 722, 865, 906, Pharmacokinetics and Pharmacodynamics: Research Design and Analysis, 117, research institute, 61, Seventh Annual Meeting, 739, Sixth Annual Meeting, 59, 148, 198, 258, 358, 482, Symposium, 76; International Symposium on Management of Clinical Pharmacy Services, 737; journal of Pharmacy Technology, manuscript submission, 148, 238, 340, 492, 869, subscription information, 36, ibc-Fe, 184, 244, 367, 476, 665, 783; M.D. Anderson Hospital, Pharmacy Symposium on Cancer Chemotherapy, 555; Ohio Conference on Clinical Pharmacy and Clinical Pharmacology, Fifth Annual, 659; St. Vincent Hospital and Health Care Center, Therapeutic Drug Monitoring: Clinical Decision Making, 121; Tufts University, Postgraduate Course, 238; University of Florida, clinical pharmacokinetics, 75
Antacids, compared with histamine$_2$-receptors (DSP) 807; duodenal ulcer healing (CTF) 775; stress ulcer prophylaxis (DSP) 807
Antal, E.J. (coauthor) see **Kubacka, Renee T.**, 461; (coauthor) see **Wright, C. Eugene III**, 458
Antiarrhythmic agents, intensive care unit syndrome (CC) 16
Antibiotics, COPD (L) 397; cost-containment (S) 278; cystic fibrosis (L) 318; home program (S) 285, 288; intravenous, home therapy (ab) 461; ophthalmic infections (A) 642; pediatric orthopedic surgery (RPR) 834; prophylaxis (CTF) 67; total joint replacements (RPR) 753; urinary tract infections (CTF) 324
Antibodies, monoclonal anti-digoxin (ab) 458
Anticholinergic agents, intensive care unit syndrome (CC) 15
Anticoagulants, clinic, cost justification (L) 947
Anticonvulsants, effect on quinidine (ab) 461; monitoring (TM) 913
Antiemetics, chemotherapy-induced emesis (OT) 21
Antipyrine, pharmacokinetics, effect of verapamil (ab) 446
Apicella, M.A. (coauthor) see **Morse, Gene D.**, 469
Appleby, Daryl H. (coauthor) see **Hittel, William P.**, 141; (coauthor) see **Van Lith, Richard M.**, 829
Araki, Mark A. (coauthor) see **Jue, Sandra G.**, 483
Arana, C.J. (coauthor) see **Lam, Y.W. Francis**, 451
Armstrong, Deborah K. (coauthor) see **Dasta, Joseph F.**, 448
Armstrong, Edward P. (author) A Survey of Prophylactic Antibiotic use for Total Joint Replacements in a Community Hospital (RPR) 753
Ascione, Frank J. (coauthor) see **Shimp, Leslie A.**, 766
Ascorbic acid, acute renal failure (CTF) 776
Aspartame, granulomatous panniculitis (CTF) 603
Aspirin, compared with dextran (CTF) 602; compared with fenoprofen, dysmenorrhea (ab) 445; compared with ibuprofen (CTF) 406; interaction, sucralfate (ab) 457; pharmacokinetics (ab) 461; stomach damage (CTF) 491
Assays, differences, aminoglycoside pharmacokinetics (ab) 464
Association News (NC), FIP/WHO Collaboration, 412; Parenteral Drug Association Scholar Grant Program, 80; The Federation Internationale Pharmaceutique Announces a Program for the Academic Section, 503; Three PDA Grants Announced, 159
Atenolol, compared with acebutolol, hypertension (CTF) 775; compared with bendroflauzide (A) 632; pregnancy-associated hypertension (CTF) 227
Atracurium, neuromuscular blockade (CTF) 405
Atropine, myopia (CTF) 776; sulfate, inhalation (DIAS) 732, pH, cardiac arrest (ab) 449
Atwood, Beverly F. (coauthor) see **Shimp, Leslie A.**, 766
Avello, Fernando (coauthor) see **Criado, Antonio**, 673
Azathioprine, compared with d-penicillamine (CTF) 228; sarcoidosis, (DIAS) 910
Azlocillin, pharmacokinetics (ab) 459; pharmacokinetics, dosage comparison (ab) 450
Aztreonam, adverse effects (FF) 173; evaluation (FF) 171; pharmacokinetics (FF) 172

B

Babington, Maude A., Clinical Affairs Associate, American Pharmaceutical Association (NC) 696
Bach, David S. (author) Haloperidol-Associated Hyperthermia (L) 211; (author) The Effect of Verapamil Pretreatment on Antipyrine Pharmacokinetics in Man (ab) 446
Baclofen, hallucinations (CR) 747; voluntary abortion (CTF) 405; withdrawal (CR) 304
Bailey, Clifford C. (coauthor) see **Remington, Helen St.C.**, 372
Bailie, George R. (author) Evaluation of Digoxin Assays (ab) 468; (author) Imipenem/Cilastatin Efficacy Evaluated (L) 840
Baker, Danial E. (author) Pentoxifylline: A New Agent for Intermittent Claudication (FF) 345
Baker, James R. (coauthor) see **Grabenstein, John D.**, 679
Baker, Karen A. (author) book review, 846
Balfour, H.H. (coauthor) see **Brundage, Diane M.**, 453; (coauthor) see **Fletcher, Courtney V.**, 466
Balmer, Carol McManus (author) The New Alpha Interferons (DSP) 887
Banta, Lawrence E. (coauthor) see **Bhatia, Subhash C.**, 744
Barbarash, Rick A. (author) Continuous Verapamil Infusions in the Treatment of Atrial Tachyarrhythmias (ab) 466; (author) Verapamil-Rifampin Interaction (CR) 559; appointments at Medical University of South Carolina (NC) 616
Barber, Jacqueline R., appointments at Medical University of South Carolina (NC) 616
Barbero, Julita Rodriguez (author) Cefmetazole Plasma Levels after Intraincisional Administration (L) 394

NOTE: A key to abbreviations used is located on the last page of the index.

Barkin, Robert L. (author) Comment: Neuroleptic Malignant Syndrome (L) 211; (coauthor) see **Stein, Z.L.G.**, 398
Barletta, Michael A. (author) Isosorbide Dinitrate—Disopyramide Phosphate Interaction (L) 764
Barone, Joseph A. (author) Critical Evaluation of Thioridazine Bioequivalence (O) 847
Barr, A. (coauthor) see **Fischer, James H.**, 460
Barriere, Steven L. (author) Cost-Containment of Antimicrobial Therapy (S) 278; (coauthor) see **Alldredge, Brian K.**, 28; (coauthor) see **Earp, Colleen M.**, 677; (coauthor) see **Lau, Teresa**, 907; (coauthor) see **Warda, Janet**, 25
Barson, William J. (coauthor) see **Nahata, Milap C.**, 900
Basmadjian, Garo P. (author) book review, 404
Batey, Sharyn R. (author) Psychotropic Medication use in Chronically Mentally Ill Females (L) 844
Batra, Kumar K. (coauthor) see **Marquardt, Eric D.**, 840
Bauman, Jerry L (coauthor) see **Barbarash, Rick A.**, 466; (coauthor) see **Witte, Kenneth W.**, 452
Bawejs, Raman (author) book review, 488
Bayliff, Charles D. (author) The use of Halothane in the Treatment of Status Asthmaticus (CR) 307
Beach, C.L. (author) Analysis of a Multiple-Model Pharmacokinetic Microcomputer Program for Tobramycin (ab) 451; (coauthor) see **Farringer, John A.**, 461
Bean, Bonnie (coauthor) see **Brundage, Diane M.**, 453; (coauthor) see **Fletcher, Courtney V.**, 466, 518
Beauchamp, Catherine (author) H_1 Antagonists in Hives and Urticaria (DIAS) 662
Beauclair, Therese (coauthor) see **Sargenti, Christine**, 380
Beck, C.L. (coauthor) see **Gonzalez, Edgar R.**, 449
Beck, Diane E. (author) Prediction of Free Phenytoin Serum Concentrations in the Clinical Setting (ab) 469; (author) Prediction of Phenobarbital Levels in Pediatric Patients (ab) 469
Beclomethasone, asthma (DIAS) 185
Belandres, Manuel M. (coauthor) see **Eggleston, S. Mark**, 553
Bell, J.A. (coauthor) see **Steinberg, Irving**, 464
Bell, Patricia L. (coauthor) see **Parashos, Peter J.**, 139
Ben-Ari, Josef (coauthor) see **Garty, Ben-Zion**, 740
Benzodiazepines, addiction (TC) 657; sublingual (L) 839; withdrawal syndrome (CR) 742
Bera, Milan D., Jr. (coauthor) see **Cornelis, William A.**, 587
Berbatis, Con (coauthor) see **Plumridge, Richard J.**, 318
Berchou, Richard C. (author) Effect of Imipramine on Lactate and Isoproterenol-Induced Panic Attacks (ab) 449
Berdoff, Russell (coauthor) see **Goldberg, Emanuel**, 468
Berezin, Gilbert H. (author) Comment: Guidelines for IV Drugs (L) 56
Berg, H.G. (coauthor) see **Steinberg, Irving**, 464
Bergeron, Michel G. (coauthor) see **LeBel, Marc**, 932
Berman, Alex, Honorary President, American Institute of the History of Pharmacy (NC) 160
Bernstein, Linda R. (coauthor) see **Herfindal, Eric T.**, 440
Bertch, Karen E. (author) A Comparative Study of Laboratory Parameters in Head-Injured Patients Receiving Either Phenytoin or Placebo for 24 Months (RPR) 561
Berwish, Neil J. (coauthor) see **Bond, William S.**, 742
Beta-blockers, exercise (TC) 302; glucose control (A) 246; hypertension (A) 629; myocardial infarction (TC) 581; retroperitoneal fibrosis (DIAS) 359
Beta-lactams, aztreonam (FF) 171
Bethanechol, Alzheimer's disease (CTF) 324
Bhatia, Subhash C. (author) Molindone and Hepatotoxicity (CR) 744
Bialer, Meir (coauthor) see **Yacobi, Avraham**, 323
Bickers, R.G. (coauthor) see **Kuhn, Robert J.**, 445
Biermann, William A. (coauthor) see **Pietruszka Laura J.**, 31
Bioequivalence, thioridazine (O) 847
Bitolterol, asthma, compared with albuterol (CTF) 603
Bixler, Thomas J. (coauthor) see **Howard, Patricia**, 763
Blais, Francis (coauthor) see **LeFrock, Jack L.**, 309
Bleomycin, pneumonitis (CR) 921
Blevins, R. (coauthor) see **Bach, David S.**, 446
Bliss, Marla (coauthor) see **Nolan, Paul E.**, 463
Blue, Donna (coauthor) see **Rapp, Robert P.**, 214, 842
Blum, Robert A. (coauthor) see **De Vito, Joseph M.**, 837
Blumer, J.L. (coauthor) see **Cowan, Ronald I.**, 455
Bodendorfer, Thomas W. (author) Desensitization with Human (Recombinant DNA) Insulin (CR) 827
Boehm, Ralph (coauthor) see **Sargenti, Christine**, 380
Boerema, J.B.J. (coauthor) see **Dirksen, M.S.C.**, 945
Boisvert, Alain (author) book review, 69
Bolender, Barbara J. (coauthor) see **Weber, Robert J.**, 13
Bonati, Maurizio (author) Quality Control in Antiepileptic Drug Monitoring in Italy (TM) 913; (coauthor) see **Snidero, Mario**, 660
Bond, William S. (author) Severe Withdrawal Syndrome after Substitution of a Short-Acting Benzodiazepine for a Long-Acting Benzodiazepine (CR) 742
Book Reviews, A Clinical Companion to Biochemical Studies, 2nd Ed. (V. Schwarz) 600; Advances in Malaria Chemotherapy (WHO) 684; AMA Handbook of Poisonous and Injurious Plants (K.F. Lampe, M.A. McCann) 846; Antimicrobial Therapy (A.M. Ristuccia, B.A. Cunha) 845; Aspects of Psychopharmacology (D.J. Sanger, D.E. Blackman) 774; Biomedical Bestiary: An Epidemiologic Guide to Flaws and Fallacies in the Medical Literature (M. Michael, W.T. Boyce, A.J. Wilcox) 69; Clinical Guide to Parenteral Micronutrition (T.G. Baumgartner) 951; Clinical Management of Prescription Drugs (J.W. Long) 489; Clinical Pharmacology (R.H. Girdwood) 321; Clinical Pharmacology of Drug Dependence (P.F. Mannaioni) 774; Clinical Pharmacology of Skin Disease (D.R. Bickers, P.G. Hazen, W.S. Lynch) 323; Clinical Pharmacy and Therapeutics, 3rd Ed. (E.T. Herfindal, J.L. Hirschman) 403; Clinical Psychopharmacology (H. Hippius, G. Winokur) 153; Community Response to Alcohol-Related Problems (E.B. Ritson) 951; Controlled Drug Bioavailability: Bioavailability Control by Drug Delivery System Design, Vol. 3 (V.F. Smolen, L. Ball) 773; Controlled Drug Bioavailability, Vols. 1 and 2 (V.F. Smolen, L.A. Ball) 323; Cutting's Handbook of Pharmacology: The Action and uses of Drugs (T.Z. Csaky, B.A. Barnes) 488; Dependence on Tranquilizers (H. Petursson, M. Lader) 322; Drug Metabolism and Drug Toxicity (J.R. Mitchell, M.G. Horning) 226; Drug Therapy in Infants (R.J. Roberts) 404; Drug Treatment in the Elderly (R.E. Vestal) 153; Drug use in Psychiatry (L. Evans, M.J. Eadie, L. Hollister, J.H. Tyren) 69; Evaluations of Drug Interactions (A.F. Shinn) 599; Experimental and Clinical Toxicokinetics (A. Yacobi, H. Barry III) 600; Fundamentals of Nuclear Medicine (N.P. Alazraki, F.S. Mishkin) 404; Guide to Clinical Studies and Developing Protocols (B. Spilker) 488; Guidelines for Investigating Alcohol Problems and Developing Appropriate Responses (I. Rootman, J. Moser) 322; Handbook of Ocular Pharmacology 3rd. Ed. (M.B. Smith) 599; Introduction to Dialysis (M.G. Cogan, M.R. Garovoy) 683; Medicinal Chemistry (T. Nogrady) 684; Modern Methods in Pharmacology, Vol 2. (S. Spector, N. Back) 403; Most-Prescribed Drugs 1985 (R.J. Tallarida) 601; New Drugs Annual: Cardiovascular Drugs Vol. 2 (A. Scriabine) 488; Nitrous Oxide (E.I. Eger II) 846; Nomograms for Administration of Critical Care Drugs (J.E. Rueter, P.J. Miller) 321; Orphan Drugs (C. Asbury) 683; Pharmacokinetics of Sulfonamides Revisited (T.B. Vree, Y.A. Hekster) 773; Pharmacologic Aspects of Aging (L.A. Pagliaro, A.M. Pagliaro) 69; Pharmacological Aspects of Nursing Care (B.S. Reiss, M.E. Melick) 226; Practice of Critical Care Pharmacy (T.C. Majerus, J.F. Dasta) 599; Principles of Clinical Toxicology (T.A. Gossel, J.D. Bricker) 600; Principles of Paediatric Pharmacology (G.M. Maxwell) 225; Psychopharmacology: Part I: Preclinical Psychopharmacology (D.G. Grahame-Smith, P.J. Cowen) 153; Psychopharmacology: Part II: Clinical Psychopharmacology (H. Hippius, G. Winokur) 153; Side Effects of Drugs Annual 8 (M.N.G. Dukes, J. Elis) 225; The Aging Process: Therapeutic Implications (R.N. Butler, A.G. Bearn) 773; The Biochemical Effects of Drugs in Pregnancy, Vols. 1 and 2 (A. Onnis, P. Greila) 683; The Determination of Ionization Constants, 3rd. Ed. (A.rio Albert, E.P. Serjeant) 601; Theoretical Drug Design Methods (R. Frank) 322; Transdermal and Related Drug Delivery Systems (D.A. Jones) 321; USAN and the USP Dictionary of Drug Names (U.S. Pharmacopeial Convention) 489; 1984 Year Book of Drug Therapy (L.E. Hollister, L. Lasagna) 225
Books Received, 153, 323, 489, 684, 774
Boran, K.J. (coauthor) see **Lehmann, Craig R.**, 460
Bosso, John A. (author) Feasibility and Cost Savings of Intravenous Administration of Aminoglycosides in Outpatients with Cystic Fibrosis (RPR) 52
Bottorff, Michael B. (author) Lidocaine Pharmacokinetics Following Epidural Administration to Pre-Eclamptic Patients (ab) 456; (coauthor) see **Lalonde, Richard L.**, 449; (coauthor) see **Phelps, Stephanie J.**, 466
Botulinum toxin, benign essential blepharospasm (CTF) 953; blepharospasm (CTF) 152
Boucher, Charles A. (coauthor) see **Ameer, Barbara**, 457
Bowden, T.A. (coauthor) see **DiPiro, Joseph T.**, 446
Boyd, Eddie L. (author) book review, 489
Boylen, C.T. (coauthor) see **Gilman, Thomas M.**, 453
Bozzino J. (coauthor) see **Jackson, M.**, 841
Bradberry, J. Chris (author) book review, 225
Brehm, J. (coauthor) see **MacCosbe, Paul E.**, 446
Brinkman, Joseph H. (coauthor) see **Tao, Glen K.**, 548
Britton, Mark L. (author) Central Nervous System Toxicity Associated with Concurrent use of Triazolam and Cimetidine (CR) 666
Bromer, Richard (coauthor) see **Cersosimo, Robert J.**, 118
Bromocriptine, Parkinson's disease (CTF) 685; premenstrual syndrome (A) 717
Bronchodilators, ipratropium bromide (ID) 5
Brown, D. (coauthor) see **Reedy, Michael E.**, 457
Brown, David C. (coauthor) see **Lake, Kathleen D.**, 530
Brown, Morris E. (coauthor) see **Bodendorfer, Thomas W.**, 827
Browne, Jerry L. (author) book review, 774
Brundage, Diane M. (author) Acyclovir Disposition in Critically Ill Patients with Herpes Virus Infections on Continuous Peritoneal Dialysis (ab) 453; (coauthor) see **Fletcher, Courtney V.**, 466
Brundage, Richard C., director, Clinical Pharmacokinetics Service, Medical University of South Carolina (NC) 880
Brushwood, David B. (author) A Third Class of Drugs: An Overview (O) 62
Bucindolol, compared with diuretic, propranolol, hydralazine (ab) 454; hemodynamic effects (ab) 453; pharmacokinetics, hypertension (ab) 453
Bulko, Deborah (coauthor) see **Ameer, Barbara**, 457
Bumetanide, hemodynamic effects (ab) 453
Buncher, C. Ralph (author) book review, 69
Bupropion, Parkinson's disease (CTF) 67; stability (ab) 447
Burckart, Gilbert J. (author) Ceftizoxime and Cefotaxime Pharmacokinetics in Pediatric Liver Transplant Patients (ab) 450; (coauthor) see **Howrie, Denise L.**, 425; (coauthor) see **Ptachcinski, Richard J.**, 90, 450; (coauthor) see **Venkataramanan, Raman**, 451
Burkle, Wayne S. (author) Cyclosporine Pharmacokinetics and Blood level Monitoring (A) 101; (coauthor) see **Hunt, Stephanie A.**, 465
Burnakis, Thomas G. (author) Comment: Cephalosporins in Surgical Prophylaxis (L) 586; (coauthor) see **Miodu ch, James**, 211
Burns, Elizabeth A. (coauthor) see **True, Bev Lorraine**, 714, 729
Burns, J. Michael, section head, Norwich Eaton Pharmaceuticals (NC) 80
Burt, R.A.P. (coauthor) see **Osathanondh, Rapin**, 445
Buspirone, addiction (TC) 657; adverse reactions (FF) 625; compared with clorazepate (FF) 627; compared with diazepam (FF) 627; evaluation (FF) 624; pharmacokinetics (FF) 625
Bussey, Henry I. (author) Comment: Pharm.D. Faculty in Medical Schools (L) 948; (author) Digoxin vs. Digitoxin in the Treatment of Congestive Heart Failure (ab) 458; (author) Practical Value of a New Serum Digitoxin Assay (ab) 458; (coauthor) see **Talbert, Robert L.**, 456

C

Cabana, B.E. (coauthor) see **Straughn, Arthur B.**, 461
Cady, William J. (author) book review, 488
Caffeine citrate, compared with theophylline (L) 762
Calcium chloride, cardiopulmonary resuscitation (ab) 460; pH, cardiac arrest (ab) 449
Calcium gluconate, sodium fluoride, vitamin D, otospongiosis (CTF) 775
Calculator, programmable, pharmacokinetic analysis (RPR) 125
Caldwell, B.V. (coauthor) see **Osathanondh, Rapin**, 445
Caldwell, R. Dewayne, appointments at Medical University of South Carolina (NC) 616
Calis, Karim A. (author) Sublingual use of Benzodiazepines (L) 839
Callahan, Ronald J. (coauthor) see **Ameer, Barbara**, 457
Calvert, Jon C. (coauthor) see **Longe, R. Leon**, 252
Calvo de Mora, A. (coauthor) see **Jimenez-Alonso, J.**, 477
Campbell, R. Keith (coauthor) see **Baker, Danial E.**, 345
Cancer, chemotherapy, antiemetic therapy (OT) 21
Canthaxanthine, retinopathy (CTF) 68
Captopril, acute reaction (CTF) 325; anemia (CTF) 406; aplastic anemia (CTF) 686; compared with hydrochlorothiazide (A) 632; effectiveness (CTF) 866; obstetrics (CTF) 324; verapamil, blood pressure reduction (CTF) 602
Carballo, H. (coauthor) see **Mojaverian, Parviz**, 454
Carbamazepine, erythema multiforme (CR) 114; hair loss (CR) 924; hemolytic anemia (CTF) 686; interaction, cimetidine (ab) 456; pancreatitis (CR) 925; pharmacokinetics, ranitidine (RPR) 941
Carbenicillin, gentamicin, compared with ceftazidime, cystic fibrosis (CTF) 867; tobramycin, cystic fibrosis (RPR) 757
Carmona, Juan (coauthor) see **Criado, Antonio**, 673
Carr, Bernice B. (coauthor) see **LeFrock, Jack L.**, 309
Carrico, J. (coauthor) see **Vaughan, Leigh**, 452
Carson, Stanley W. (author) Evaluation of Serum Dexamethasone Concentrations in Psychiatric Patients Undergoing Suppression Testing (ab) 454
Carter, Barry (coauthor) see **True, Bev Lorraine**, 825
Carter, Charles A. (author) Terfenadine, A Nonsedating Antihistamine (FF) 812
Case Reports see **Clinical Pharmacy Case Reports**
Castelli, Donata (coauthor) see **Bonati, Maurizio**, 913
Catania, Patrick N. (coauthor) see **Mikhail, May N.**, 447
Cate, E.W. (author) Cimetidine, but not Ranitidine, Inhibits Tolbutamide Elimination (ab) 465
Cathartics, slow-release drug absorption (ab) 462
Caustics, alkaline, esophageal injury (CTF) 68
Cefaclor, compared with amoxicillin/potassium clavulanate, otitis media (CTF) 776; compared with trimethoprim/sulfamethoxazole (CTF) 152; serum sickness (DIAS) 186
Cefamandole, compared with cefazolin (RPR) 677; compared with moxalactam (RPR) 677; pharmacokinetics (ab) 460
Cefazolin, compared with cefamandole (RPR) 677; compared with moxalactam (RPR) 677
Cefmetazole, serum levels (L) 394
Cefonicid, adverse reactions (DSP) 193
Cefoperazone, amikacin, neutropenic cancer patients (CTF) 602; bactericidal activity (CTF) 952
Ceforanide, adverse reactions (DSP) 190; pharmacokinetics (DSP) 190
Cefotaxime, bactericidal activity (CTF) 952; compared with ampicillin, chloramphenicol, bacterial meningitis (CTF) 953; pharmacokinetics, obesity (ab) 463; pharmacokinetics, pediatric liver transplant (ab) 450
Cefoxitin, compared with cephalothin, cesarean section (ab) 447
Ceftazidime, adverse reactions (FF) 510; compared with gentamicin/carbenicillin, cystic fibrosis (CTF) 867; evaluation (FF) 509; netilmicin, bactericidal activity (RPR) 932; pharmacokinetics (FF) 510
Ceftizoxime, bactericidal activity (CTF) 952; pharmacokinetics, pediatric liver transplant (ab) 450
Ceftriaxone, adverse effects (FF) 901; evaluation (FF) 900; pharmacokinetics (FF) 900
Cefuroxime, adverse reactions (DSP) 190; pharmacokinetics (ab) 460, (DSP) 190
Cellulose sodium phosphate, adverse reactions (DSP) 533; evaluation (DSP) 533
Cephalosporins, bactericidal activity (CTF) 952; ceftriaxone evaluation (FF) 900; costs (L) 211; dosing (L) 843; jaundice (CR) 553; prophylaxis (TC) 214; second-generation (DSP) 188; surgical prophylaxis (L) 842
Cephalothin, compared with cefoxitin, cesarean section (ab) 447
Cephradine, metronidazole, intraperitoneal abscess (CTF) 685
Cersosimo, Robert J. (author) Bleomycin Pneumonitis Potentiated by Oxygen Administration (CR) 921; (author) The Antiemetic Activity of Droperidol Administered by Intramuscular Injection During Cisplatin Chemotherapy: A Pilot Study (RPR) 118
Ceruletide, compared with pentazocine (RPR) 433; renal colic (RPR) 433

Chan, Beatrice (author) Pneumococcal Vaccine for Acute Otitis Media (DIAS) 735
Chandrasekar, Pranatharthi H. (coauthor) see **Gutschi, L. Maria**, 762
Chang, C.W. (coauthor) see **Lau, Alan**, 457
Charcoal, activated, adsorptive capacity (CTF) 228; digoxin/digitoxin clearance (ab) 447, (RPR) 937
Chinnock, B. (coauthor) see **Brundage, Diane M.**, 453; (coauthor) see **Fletcher, Courtney V.**, 466
Chlorambucil, compared with methotrexate, sarcoidosis (DIAS) 909
Chloramphenicol, ampicillin, compared with cefotaxime, bacterial meningitis (CTF) 953
Chlorazepate, central nervous system symptoms (RPR) 38
Chlordiazepoxide, central nervous system symptoms (RPR) 38
Chlorpromazine, chemotherapy-induced emesis (OT) 23; meperidine, promethazine, pediatrics, respiratory depression (ab) 445
Chlorpropamide, amiloride interaction (CTF) 152; hepatotoxicity (CTF) 228
Choi, K.E. (coauthor) see **Christensen, M.L.**, 467
Chow, Moses Sing Sum (author) Estimation of Creatinine Clearance in Patients with Unstable Serum Creatinine Concentrations: Comparison of Multiple Methods (RPR) 385; (author) The Hemodynamic Effects of Epinephrine and Calcium Chloride During Cardiopulmonary Resuscitation (ab) 460; (coauthor) see **Hanyok, J.J.**, 459
Chretien, Steven D. (coauthor) see **Gray, David R.**, 575
Christensen, Dale B. (coauthor) see **Horn, John R.**, 45
Christensen, M.L. (author) Evaluation of Monitoring Criteria for High-Dose Methotrexate in Children with Acute Lymphocytic Leukemia (ab) 467
Chymopapain, anaphylaxis (CTF) 68, (DIAS) 26; cerebral hemorrhage (CTF) 68; herniated lumbar disc (CTF) 775; IgE determinations (CTF) 405; product equivalency (L) 398
Cilastatin, see **Imipenem, cilastatin**
Cimetidine, arthritis (CR) 201; CNS toxicity (CR) 666; compared with antacids (DSP) 807; compared with misoprostol, duodenal ulcer (CTF) 866; compared with Mylanta, gastric ulcer (CTF) 952; compared with ranitidine (CTF) 490; compared with sucralfate (CTF) 490; diarrhea (DIAS) 185; effect on glyburide pharmacokinetics (ab) 461; eosinophilia (CR) 377; hepatic blood flow (RPR) 831; interaction, carbamazepine (ab) 456; pharmacokinetics (CR) 203; prolonged sedation (L) 679; stress ulcer prophylaxis (DSP) 807; tolbutamide elimination (ab) 465; ulcer recurrence (CTF) 151; urticaria (DIAS) 662
Cipolle, Robert J. (coauthor) see **Steinberg, Irving**, 464
Ciprofloxacin, pharmacokinetics (ab) 462
Cisplatin, chemotherapy-induced emesis (OT) 23; droperidol antiemetic activity (RPR) 118; effect on methotrexate (ab) 467; interactions, lithium (CR) 31; nephrotoxicity (OT) 362; sodium thiosulfate, nephrotoxicity (CTF) 603
Clark, Beverly G. (author) Phenytoin Once-Daily Dosing in Geriatric Patients (L) 584; (coauthor) see **Jue, Sandra G.**, 483
Clark, G. (coauthor) see **Kuhn, John**, 457
Clarke, Diana F. (author) Comment: Antibiotic use in Cystic Fibrosis (L) 318
Clavulanic acid, amoxicillin, review (TC) 475
Clementi, William A. (coauthor) see **Conner, Dale P.**, 453; (coauthor) see **Farringer, John A.**, 461; (coauthor) see **Watson, William A.**, 458
Clindamycin, age, pharmacokinetics (ab) 450; gentamicin, compared with imipenem/cilastatin (ab) 455, 466
Clinical Pharmacy Case Reports, A Possible Case of Carbamazepine-Induced Pancreatitis, 925; A Warfarin-Piroxicam Drug Interaction, 556; Accidental Massive IV Administration of Cyclosporine in Man, 29; Adverse Effects Secondary to Baclofen Withdrawal, 304; Amoxapine-Induced Tardive Dyskinesia, 548; Anaphylactoid Reactions Associated with Parenteral Cyclosporine use: Possible Role of Cremophor El, 425; Bleomycin Pneumonitis Potentiated by Oxygen Administration, 953; Carbamazepine-Induced Hair Loss, 924; Central Nervous System Toxicity Associated with Concurrent use of Triazolam and Cimetidine, 666; Cimetidine-Induced Eosinophilia, 377; Desensitization with Human (Recombinant DNA) Insulin, 827; Drug-Induced Erythema Multiforme: A Possible Immunologic Pathogenesis, 114; Enhanced Theophylline Clearance Secondary to Phenytoin Therapy, 34; Evaluation of Cisplatin-Lithium Interaction, 31; Gout-Like Arthritis Following Cimetidine and Ranitidine, 201; Guanabenz Therapy for Opiate Withdrawal, 32; Hallucinations after Preoperative Baclofen Discontinuation in Spinal Cord Injury Patients, 747; Hepatitis Associated with Allopurinol, 431; Hepatitis Associated with Propylthiouracil Treatment, 740; Hypersensitivity Reaction to Mannitol, 552; Jaundice Associated with Cephalosporin Therapy, 553; Lidocaine-Induced Second-Degree Mobitz Type II Heart Block, 669; Methotrexate Blood Level Monitoring, 372; Molindone and Hepatotoxicity, 744; Neutropenia Associated with Mezlocillin and Piperacillin, 112; Phenytoin Clearance by Continuous Ambulatory Peritoneal Dialysis, 429; Prolonged Elimination of Piperacillin in a Patient with Renal and Liver Failure, 427; Quinidine-Nifedipine Interaction, 829; Recurrent Dystonic Reactions Induced by Thiethylperazine, 550; Seizures Following Oral Lidocaine for Esophageal Anesthesia, 199; Severe Withdrawal Syndrome after Substitution of a Short-Acting Benzodiazepine for a Long-Acting Benzodiazepine, 742; Switching Monoamine Oxidase Inhibitors, 825; The Effect of Sulindac on Lithium Therapy, 374; The Management of Preterm Labor with the Calcium Channel-Blocking Agent Nifedipine Combined with the Beta-Mimetic Terbutaline, 369; The Pharmacokinetics of Cimetidine and Metabolites in a Neonate, 203; The use of Halothane in the Treatment of Status Asthmaticus, 307; Verapamil-Rifampin Interaction, 559
Clinical Trials, Regression to the Mean: A Potential Source of Error in Clinical Pharmacological Studies, 916
Clinics, veterinary, pharmacy education (RPR) 315
Clonazepam, mania, schizoaffective disorder (CTF) 68; restless leg syndrome (CTF) 67; valproate, seizure improvement (CTF) 866
Clonidine, compared with chlorthalidone (A) 632; compared with lofexidine, essential hypertension (RPR) 928; compared with verapamil, acute mania (CTF) 867; diabetic diarrhea (CTF) 602; hyperhydrosis (CTF) 324; pain control (CTF) 685; phonic tics (CTF) 685; premenstrual syndrome (CTF) 405; transdermal (CTF) 324; withdrawal symptoms (CTF) 406
Clorazepate, compared with buspirone (FF) 627; compared with diazepam (FF) 627
Clotz, M.A. (coauthor) see **Nahata, Milap C.**, 445
Coats, Eugene A. (author) book review, 684
Cocaine, compared with lidocaine (CTF) 227; myocardial infarction (CTF) 325; pseudomembrancus colitis (CTF) 776; trazodone interaction (CTF) 68
Cochran, Emily (coauthor) see **Stewart, Clinton F.**, 451
Colaizzi, John L. (coauthor) see **Barone, Joseph A.**, 847
Colchicine, idiopathic thrombocytopenia purpura (CTF) 324; urticarial vasculitis (CTF) 866
Collier, Robert E. (coauthor) see **Elenbaas, Robert M.**, 567
Collins, G.E. (coauthor) see **Markiewicz, Michael A.**, 447
Collins, M.B. (coauthor) see **Gilman, Miles E.**, 446
Collins, M.S. (coauthor) see **Gonzalez, Edgar R.**, 449
Colvin, Carol L. (author) Pimozide: Use in Tourette's Syndrome (FF) 421; (coauthor) see **Alexander, Michael R.**, 403
Compliance, dapsone (ab) 464
Comstock, Thomas J. (author) Free Serum and Urine Phenytoin Levels at Various Degrees of Kidney Function (ab) 465; (author) Phenytoin Disposition and Protein Binding during Continuous Ambulatory Peritoneal Dialysis (ab) 465
Conboy, C. (coauthor) see **Vaughan, Leigh**, 452
Congestive heart failure, digoxin vs. digitoxin (ab) 458
Conner, Christopher S. (author) Author's Reply: Mitoxantrone (O) 218; (author) Therapeutic Controversies: Beta-Lactamase Inhibitors, 475; (editor) Therapeutic Controversies, 214, 302, 581, 657, 729, 911
Conner, Dale P. (author) Hemodynamic Effects of Bucindolol at Rest and during Exercise in Hypertensive Men (ab) 453
Connors, Richard (author) Comment: Cimetidine Kinetics in Neonate (L) 588
Conte, Ronald R. (author) Comment: Anticoagulation Clinic Cost Justification (L) 947
Continuing education, see **Drug Intelligence and Clinical Pharmacy, PharmaCE**; survey (RPR) 134
Contraceptives, oral, menopause (CTF) 953
Corbin, Richard P. (coauthor) see **Fraser, Gilles L.**, 757
Cornelis, William A. (author) Comment: Amphotericin B Bladder Irrigations (L) 587
Corticosteroids, see **Steroids, cortico-**
Cost-containment, antimicrobials (S) 278; health care (S) 291; theophylline (RPR) 749
Co-trimoxazole, compared with trimethoprim (CTF) 490; urinary tract infection, renal transplant (ab) 452
Cowan, Ronald I. (author) Cerebrospinal Fluid Penetration of Moxalactam in Ventriculostomy Patients (ab) 455
Cox, S.R. (coauthor) see **Townsend, Raymond J.**, 447
Coyne, M.R. (coauthor) see **Gonzalez, Edgar R.**, 449
Cruss, Richard E. (author) Authors' Reply: Monitoring Pediatric IV Drugs (L) 210; (coauthor) see **De Vito, Joseph M.**, 837
Crawford, M.H. (coauthor) see **Talbert, Robert L.**, 456
Creatinine, clearance estimation (RPR) 385
Creger, R.J. (coauthor) see **Cowan, Ronald I.**, 455; (coauthor) see **Danziger, Larry H.**, 455; (coauthor) see **Glazier, Howard S.**, 466
Cremer, Karl F. (coauthor) see **Pieper, John A.**, 465
Cremophor El, anaphylaxis (CR) 425
Criado, Antonio (author) Ticlopidine as a Hemorrhagic Risk Factor in Coronary Surgery (RPR) 673
Critical Care Therapeutics, Hepatic Drug Clearance Following Traumatic Injury, 799; The Intensive Care Unit Syndrome: Causes, Treatment, and Prevention, 13
Crom, William R. (author) The Intrapatient Effect of Cisplatin Therapy on the Pharmacokinetics of High-Dose Methotrexate (ab) 467; (coauthor) see **Teresi, Mary E.**, 466
Cromolyn, asthma (DIAS) 185; compared with theophylline (CTF) 152; sodium, atopic eczema (CTF) 685, compatibility (CTF) 228, conjunctivitis (CTF) 68
Cronin, Carol M. (author) Fellowship and Residency Announcements (L) 586
Crossley, Kent B. (coauthor) see **Bailie, George R.**, 840
Cubberley, R.B. (author) Labetalol as Monotherapy in Hypertensive Black Patients Previously Controlled on a Diuretic and a Beta-Adrenergic Blocker (ab) 456
Cumbo, T.J. (coauthor) see **Nix, David E.**, 462
Cummings, Doyle M. (author) Lack of Interference of Pentoxifylline and its Major Metabolite with Theophylline Assays (ab) 467
Current Therapeutic Findings, 67, 151, 227, 324, 405, 490, 602, 685, 775, 866, 954
Cyclobenzaprine, acute mania (CTF) 406
Cyclophosphamide, compared with doxorubicin/lomustine (CTF) 491; Prinzmetal's angina (CTF) 953; Takayasu's disease (L) 477
Cyclosporine, absorption (ab) 450; adverse effects (NDE) 95; anaphylaxis (CR) 425, 686; aplastic anemia (CTF) 775; bioavailability, liver disease (ab) 451; compared with methotrexate, marrow transplantation (CTF) 953; diabetes (CTF) 490; disposition, liver disease (ab) 451; evaluation (NDE) 90; interactions (A) 102; monitoring (A) 101; monitoring, renal transplant (ab) 454; mycosis fungoides (CTF) 755; neurotoxicity (CTF) 325; overdose, pharmacokinetics (CR) 29; pharmacokinetics (A) 101, (NDE) 91; renal dysfunction (ab) 445; renal transplant rejection (CTF) 325
Cystic fibrosis, aminoglycosides, outpatient therapy (RPR) 52; antibiotics (L) 318; tobramycin-carbenicillin therapy (RPR) 757
Cytosine arabinoside, non-Hodgkin's lymphoma (CTF) 406
Czajka, Peter A. (author) book review, 600

D

Dalmady-Israel, Christina (coauthor) see **Talbert, Robert L.**, 456
Dalton, Michael J. (author) Cimetidine and Carbamazepine: A Complex Pharmacokinetic Interaction (ab) 456; (author) Ranitidine does not Alter Single-Dose Carbamazepine Pharmacokinetics in Healthy Adults (RPR) 941
D'Ambrosio, R. (coauthor) see **Carson, Stanley W.**, 454
Danazol, asthma (CTF) 325; hepatocellular carcinoma (CTF) 603; idiopathic autoimmune hemolytic anemia (CTF) 685; postmenopausal hot flashes (CTF) 685; premenstrual syndrome (CTF) 775
Danzeisen, J.R. (coauthor) see **Vlasses, Peter H.**, 454
Danziger, Larry H. (author) A Randomized Trial of Gentamicin and Clindamycin vs. Imipenem-Cilastatin in Serious Infections (ab) 455; (coauthor) see **Cowan, Ronald I.**, 455
Dapsone, compliance (ab) 464; Kaposi's sarcoma (CTF) 603
D'Arcy, P.F. (author) Drug Interactions and Reactions Update: Nitrofurantoin, 540; (editor) Drug Interactions and Reactions Update, 85
D'Argenio, D.Z. (coauthor) see **Hurst, Agneta K.**, 469
Dasta, Joseph F. (author) The Effect of Low-Dose Dopamine on the Pharmacokinetics of Tobramycin in Dogs (ab) 448; (editor) Critical Care Therapeutics, 13, 799
Davies, Joy (coauthor) see **Furnell, Malcolm M.**, 374
Davis, Harry L. (coauthor) see **Self, Timothy H.**, 749
Davis, R.D. (coauthor) see **Markiewicz, Michael A.**, 447
Davis, Sharon K., appointments at Medical University of South Carolina (NC) 616
DeAngelis, C. (coauthor) see **Schentag, Jerome J.**, 462; (coauthor) see **Swanson, Douglas J.**, 467
deBlaquiere, Patricia A. (coauthor) see **Horn, John R.**, 45
Deeg, H.J. (coauthor) see **Yee, Gary C.**, 445
Deferoxamine, hearing loss (CTF) 953
Deitchman, D. (coauthor) see **Conner, Dale P.**, 453
DeJong, Douglas J. (coauthor) see **Letendre, Peter W.**, 349
Delafuente, Jeffrey C. (author) Drug-Induced Erythema Multiforme: A Possible Immunoiogic Pathogenesis (CR) 114
Dematteo, Carl D. (coauthor) see **LeFrock, Jack L.**, 309
De-Paolis, Chiara (coauthor) see **Lishner, Michael**, 433
D-penicillamine, compared with azathioprine (CTF) 228
Derendorf, Hartmut (coauthor) see **Yost, Richard L.**, 463
Derrer, S. (coauthor) see **Hassan, Erkan**, 453
Desmethylimipramine, plasma levels (CTF) 603
Desmopressin, uremia (CTF) 228
Destache, Christopher J. (coauthor) see **Hilleman, Daniel E.**, 669
Detoxification, guanabenz (CR) 32
Deutsch, S. (coauthor) see **Mirtallo, Jay M.**, 464
DeVane, C. Lindsay (author) book review, 322; (coauthor) see **Dommisse, Cynthia S.**, 624; (coauthor) see **Laizure, S.C.**, 447
De Vito, Joseph M. (author) Estimation of the Steady-State Volume of Distribution for Digoxin: A Comparison of Model-Independent Methods with a Two-Compartment Model in Healthy Volunteers (RPR) 837 (coauthor) see **Nix, David E.**, 462
Dexamethasone, chemotherapy-induced emesis (OT) 23; cisplatin-induced emesis (CTF) 325; suppression testing (ab) 454
Dextran, compared with aspirin (CTF) 602; venous thrombosis (CTF) 602
Dextrose solutions, nutritional support (A) 106
Dialysis, peritoneal, tobramycin (ab) 469
DIAS Rounds, Aminoglycoside Monitoring in the Neonate, 908; Amphotercin B Bladder Irrigations, 299; Amphotericin B Nephrotoxicity, 25; Atropine Sulfate by Inhalation, 732; Beta-Blocker-Induced Retroperitoneal Fibrosis, 359; Cimetidine-Induced Diarrhea, 185; Combined use of Cromolyn and Inhaled Steroid in Asthma, 1855; Drugs Causing Toxic Epidermal Necrolysis, 733; H_1 Antagonists in Hives and Urticaria, 662; Immunosuppressives in Sarcoidosis, 909; Medical Treatment for Antibiotic Colitis, 28; Mixing Local Anesthetics to Increase Efficacy, 663; Nitrates may not be Contraindicated in Patients with Glaucoma, 361; Pneumococcal Vaccine for Acute Otitis Media, 735; Prevention of Chymopapain Anaphylaxis, 26; Progesterone Suppositories in Premenstrual Syndrome, 297; Ranitidine and Warfarin Interaction, 664; Serum Sickness with Cefaclor, 186; Skin Testing for Anergy, 300; Steroids in the Treatment of Croup, 360; Vancomycin Nephrotoxicity, 907
Diazepam, central nervous system symptoms (RPR) 38; chemotherapy-induced emesis (OT) 23; compared with buspirone (FF) 627; compared with clorazepate (FF) 627; compared with minocycline (CTF) 686; compared with nadolol (CTF) 228; compared with oxazepam (CTF) 406; intensive care unit syndrome (CC) 16
Diazoxide, preeclampsia (CTF) 603
Dick, James D. (coauthor) see **Green, Laurence**, 427
Dickerson, Roland N. (author) book review, 951
Diethyl ether, bronchospasm (CTF) 491
Digitoxin, activated charcoal, clearance (ab) 447; (RPR) 937; compared with digoxin, congestive heart failure (ab) 458; serum assay (ab) 458

Digoxin, activated charcoal, clearance (ab) 447, (CTF) 776, (RPR) 937; anti-, monoclonal antibody (ab) 458; assays (ab) 468; atrial fibrillation (CTF) 490; compared with digitoxin, congestive heart failure (ab) 458; compared with gitoxin, cardiac failure (L) 945; -like immunoreactive substance (CTF) 466; monitoring (TM) 660; pharmacokinetic service (RPR) 45; volume of distribution (RPR) 837
Digoxin-specific antibody (Fab) fragments, toxicity reversal (CTF) 867
Dihydroergotamine, heparin, vascular spasm and gangrene (CTF) 406
Diltiazem, combined with propranolol, verapamil, or nifedipine (CTF) 685; concentrations, predictor of response (ab) 465; granulomatous hepatitis (CTF) 776; mania (CTF) 325; propranolol, paroxysmal supraventricular tachycardia (CTF) 490; Raynaud's phenomenon (CTF) 602
Dimethylsulfoxide, diabetic foot ulcers (CTF) 490
Dinoprostone, retinal hemorrhage (CTF) 953
Dionne, Roger (author) book review, 225
DiPersio, D.M. (coauthor) see **Chow, Moses Sing Sum,** 460; (coauthor) see **Hanyok, J.J.,** 459
Diphenhydramine, chemotherapy-induced emesis (OT) 23; compared with doxepin (CTF) 685; prednisone, ephedrine, high-risk radiology (CTF) 490
DiPiro, Joseph T. (author) Oral Neomycin Sulfate and Erythromycin Base Prior to Colon Surgery: A Comparison of Serum and Tissue Concentrations (ab) 446
Dipyridamole, high performance liquid chromatography assay (ab) 457; unpleasant taste (CTF) 953
Dirksen, M.S.C. (author) Pefloxacin—Aminophylline Interaction (L) 945
Diuretics, hypertension (A) 629; premenstrual syndrome (A) 718
Djaldetti, Meir (author) Propranolol's Effect on Phagocytizing Ability of Polymorphonuclears and Monocytes (L) 583
Dobutamine, dopamine, retinal infarction (CTF) 686
Docktor, William J. (coauthor) see **Rivey, Michael P.,** 908
Doluisio, James T. (coauthor) see **Talbert, Robert L.,** 448
Dominguez-Gil, Alfonso (coauthor) see **Barbero, Julita Rodriguez,** 395
Dommisse, Cynthia S. (author) Buspirone: A New Type of Anxiolytic (FF) 624
Dopamine, dobutamine, retinal infarction (CTF) 686; tobramycin pharmacokinetics (ab) 448
Dorociak, J.V. (coauthor) see **Fischer, James H.,** 460
Dosage adjustments, pneumonia (ab) 462
Doxepin, chronic idiopathic urticaria (CTF) 685; compared with alprazolam (CTF) 491; compared with diphenhydramine (CTF) 685
Doxorubicin, cardiotoxicity (OT) 259; chemotherapy-induced emesis (OT) 23; lomustine, compared with cyclophosphamide, prostatic carcinoma (CTF) 491
DPT vaccine, frequency (CTF) 68; seizures (CTF) 68
Drechsler-Martell, Clifford R. (coauthor) see **Jackson, Max G.,** 205
Droperidol, antiemetic activity (RPR) 118; antiemetic efficacy (L) 841; chemotherapy-induced emesis (OT) 23
Drug administration, intravenous, prospective payment (E) 146
Drug evaluations see **Drug Selection Perspectives; Formulary Forum; Investigational Drug Information; New Drug Evaluations**
Drug information, educational influences (RPR) 390; journals (L) 765; side effect perception (L) 213
Drug Information Analysis Service see **DIAS Rounds**
Drug Intelligence and Clinical Pharmacy, abstracted and indexed, 4, 82, 164, 242, 335, 414, 508, 622, 698, 794, 882; **advertising inquiries,** 3, 81, 163, 241, 334, 413, 507, 621, 697, 793, 881; **announcements,** see **Announcements;** author guidelines, 3, 81, 163, 241, 334, 413, 507, 621, 697, 793, 881; **back issues,** 145, 224, 329, 411, 420, 566, 661, 761, 806, 899; **bound volumes,** 340, 492; **column editors,** 4, 82, 164, 242, 335, 414, 508, 622, 698, 794, 882; **editorial council and panels,** ibc-Ja, ifc-Fe, ibc-Ma, ifc-Ap, ibc-My, ifc-Je, ibc-Se, ifc-Oct, ibc-Nov, ifc-Dec; **panel contributions,** Cardiology, 514, 703, Clinical Trials, 916, Critical Care, 13, 799, Infectious Disease, 171, 415, 509, Oncology, 259, 362, Psychiatry, 624; **PharmaCE,** application form, 2, 83, 170, 243, 341, 493, 604, 699, 795, 883; description, 2, 83, 170, 243, 341, 493, 604, 699, 795, 883; educational consultants, 2, 158, 170, 243, 341, 502, 558, 604, 688, 699, 795, 883; test questions, 77, 157, 234, 329, 410, 501, 605, 687, 786, 877, 960; **reprint information,** 3, 74, 81, 232, 398, 589, 689, 737, 869, 915; **subscription information,** obc-Ja, Fe, Ma, Ap, My, Je, J/A, Se, Oct, Nov, Dec; **subscription rates,** 3, 81, 163, 241, 334, 413, 507, 621, 697, 793, 881
Drug interactions, aminophylline—pefloxacin (L) 945
aspirin—sucralfate (ab) 457
carbamazepine—cimetidine (ab) 456
cimetidine—carbamazepine (ab) 456
cimetidine—triazolam (L) 679
cisplatin—lithium (CR) 31
cyclosporine—rifampin (L) 763
cyclosporine—vaccination (L) 679
disopyramide phosphate—isosorbide dinitrate (L) 764
isosorbide dinitrate—disopyramide phosphate (L) 764
lithium—cisplatin (CR) 31
methylprednisolone—piroxicam (L) 478
nifedipine—quinidine (CR) 829
pefloxacin—aminophylline (L) 945
phenytoin—theophylline (CR) 34
piroxicam—methylprednisolone (L) 478
piroxicam—warfarin (CR) 556
quinidine—nifedipine (CR) 829
ranitidine—warfarin (DIAS) 664
rifampin—cyclosporine (L) 763
rifampin—verapamil (CR) 559
sucralfate—aspirin (ab) 457
theophylline—phenytoin (CR) 34
triazolam—cimetidine (L) 679
vaccination—cyclosporine (L) 679
verapamil—rifampin (CR) 559
warfarin—piroxicam (CR) 556
warfarin—ranitidine (DIAS) 664
Drug Interactions (CTF), alprazolam—digoxin, 406
amiloride—chlorpropamide, 152
aminoglycosides—indomethacin, 686
amiodarone—phenytoin, 325
antineoplastic agents—warfarin, 603
aspirin—dipyridamole, 776
calcium—iron, 866
carbamazepine—erythromycin, 491
carbamazepine—haloperidol, 867
chlorpropamide—amiloride, 152
cimetidine—quinidine, 228
cimetidine—verapamil, 953
cocaine—trazodone, 68
dantrolene—vecuronium, 686
digoxin—alprazolam, 406
dipyridamole—aspirin, 776
erythromycin lactobionate—warfarin, 406
erythromycin—carbamazepine, 491
erythromycin—theophylline, 152
food—theophylline, 325
haloperidol—carbamazepine, 867
indomethacin—aminoglycosides, 686
indomethacin—triamterene, 867
insulin—protamine, 325
iron—calcium, 866
iron—magnesium, 866
L-tryptophan—tranylcypromine, 776
magnesium—iron, 866
metoprolol—verapamil, 953
phenytoin—amiodarone, 325
protamine—insulin, 325
quinidine—cimetidine, 228
quinidine—verapamil, 491
theophylline—erythromycin, 152
theophylline—food, 325
theophylline—vidarabine, 68
tranylcypromine—L-tryptophan, 776
trazodone-cocaine, 68
triamterene—indomethacin, 867
vecuronium—dantrolene, 686
verapamil—cimetidine, 953
verapamil—metoprolol, 953
verapamil—quinidine, 491
vidarabine—theophylline, 68
warfarin—antineoplastic agents, 603
warfarin—erythromycin lactobionate, 406
Drug Interactions and Reactions Update, Nitrofurantoin, 540; Systemic Side Effects Associated with the Ophthalmic Administration of Timolol, 85
Drug monitoring, pharmacy-based service (TM) 818
Drug Selection Perspectives, New Drug Therapy for Kidney Stones: A Review of Cellulose Sodium Phosphate, Acetohydroxamic Acid, and Potassium Citrate, 530; Prophylaxis of Stress Ulcers: Antacid Titration vs. Histamine$_2$-Receptor Blockade, 807; Review of the New Second-Generation Cephalosporins: Cefonicid, Ceforanide, and Cefuroxime, 188; The New Alpha Interferons, 887
Drugs, cost (RPR) 440; therapeutic monitoring (TM) 473; third class (O) 62
Drugs, Adverse Drug Reactions (CTF), acetaminophen, hepatotoxicity, 603; **alprazolam,** stuttering, 867, withdrawal syndrome, 491; **amiodarone,** death, 152, epidermal necrolysis, 953; **ascorbic acid,** renal failure, 776; **aspartame,** granulomatous panniculitis, 605; **aspirin,** stomach damage, 491; **cantharxanthine,** retinopathy, 68; **captopril,** acute reaction, 325, anemia, 406, aplastic anemia, 686; **carbamazepine,** hemolytic anemia, 686; **chlorpropamide,** hepatotoxicity, 228; **chymopapain,** anaphylaxis, 68, cerebral hemorrhage, 68; **cocaine,** myocardial infarction, 325, pseudomembranous colitis, 776; **cyclobenzaprine,** acute mania, 406; **cyclophosphamide,** Prinzmetal's angina, 953; **cyclosporine,** anaphylaxis, 686, neurotoxicity, 325; **danazol,** hepatocellular carcinoma, 603; **deferoxamine,** hearing loss, 953; **diazepam,** abuse liability, 406; **dihydroergotamine,** heparin, vascular spasm and gangrene, 406; **diltiazem,** granulomatous hepatitis, 776, mania, 325; **dinoprostone,** retinal hemorrhage, 953; **dipyridamole,** unpleasant taste, 953; **dobutamine,** dopamine, retinal infarction, 686; **dopamine,** dobutamine, retinal infarction, 686; **DPT vaccine,** review, 68, seizures, 68; **fat emulsions,** incidence, 867; **fluphenazine,** priapism, 867; **hemicidrin,** hypermagnesemia, 228; **heparin,** dihydroergotamine, vascular spasm and gangrene, 406, hyperkalemia, 867; **hydralazine,** glomerulonephritis, 406; **ibuprofen,** ventricular septal rupture, 953; **indomethacin,** intestinal perforations, 603; **isoproterenol,** aerosol, penny aspiration, 68; **isotretinoin,** arthritis, 152, galactorrhea, 686; **lithium,** seizures, 228, thrombophlebitis, 152; **magnesium sulfate,** paralytic ileus, 603; **maprotiline,** seizures, 776; **marijuana,** intrauterine growth retardation, 866; **methylergometrine,** bronchospasm, 867; **metronidazole,** peripheral neuropathy, 686; **mineral oil,** pneumonia, 68; **morphine,** tonic seizure, 686; **moxalactam,** prolonged prothrombin time, 491, pulmonary hemorrhage, 228; **nadolol,** infiltrative dermatitis, alopecia, 603; **nalidixic acid,** thrombocytopenia, 325, toxicity, 491; **netilmicin,** nephrotoxicity, 406; **nifedipine,** nephrotoxicity, 406, periorbital edema, 867; **oxazepam,** abuse liability, 406; **penicillamine,** dermatosis, 776; **phenelzine,** acute organic psychosis, 603, pyridoxine deficiency, 228; **phenophthalein,** pancreatitis, 152; **phenylpropanolamine,** intracerebral hemorrhage, 686; **piroxicam,** acute interstitial nephritis, 686; **prazosin,** anaphylaxis, 686; **procainamide,** neutropenia, 867; **propranolol,** mania, 491; **pyridoxine,** premenstrual syndrome, 867; **quinine,** blindness, 603; **ranitidine,** bradycardia, drowsiness, 776; **streptokinase,** bleeding, 152; **sulfacetamide,** erythema multiforme, 776; **sulfasalazine,** infertility, 228; **sulindac,** parkinsonism, 491; **tamoxifen,** endometrial cancer, 603; **timolol maleate,** myasthenia gravis deterioration, 603; **tocainide,** liver necrosis, 406; **trazodone,** atrial fibrillation, 867, complete heart block, 491, ejaculatory inhibition, 228, hepatotoxicity, 953, mania, 152, peripheral edema, 867, tonic-clonic seizures, 776; **triazolam,** overdose, 867; **valproic acid,** decreased selenium, 228; **verapamil,** angina, 152, ventricular tachycardia, 953; **vincristine,** hepatotoxicity, 228
Drugs, adverse reactions, acetaminophen, overdose toxicity (TC) 911; allopurinol, hepatitis (CR) 431; **amoxapine,** tardive dyskinesia (CR) 548; **amphotericin B,** phlebitis (RPR) 436; **antianxiety agents,** central nervous system symptoms (RPR) 37; **baclofen,** hallucinations (CR) 747, withdrawal (CR) 304; **benzodiazepines,** withdrawal syndrome (CR) 742; **beta-blockers,** retroperitoneal fibrosis (DIAS) 359; **bleomycin,** pneumonitis (CR) 921; **carbamazepine,** erythema multiforme (CR) 114, hair loss (CR) 924, pancreatitis (CR) 925; **cephalosporins,** jaundice (CR) 553; **chlorpromazine,** pediatrics, respiratory depression (ab) 445; **cimetidine,** arthritis (CR) 201, CNS toxicity (CR) 666; eosinophilia (CR) 377; **cisplatin,** nephrotoxicity (OT) 362; **clonidine,** dizziness (CR)32; **Cremophor El,** anaphylaxis (CR) 425; **cyclosporine,** anaphylaxis (CR) 425, overdose (CR) 29, renal dysfunction (ab) 445; **doxorubicin,** cardiotoxicity (OT) 259; **ethanol,** hypoglycemia (L) 480; **haloperidol,** hyperthermia (L) 211; **inservice education** (G) 483; **lidocaine,** heart block (CR) 669, seizures (L) 680, (CR) 199; **mannitol,** hypersensitivity (CR) 552; **meperidine,** pediatrics, respiratory depression (ab) 445; **methotrexate,** gastrointestinal symptoms (A) 355, toxicity (CR) 372; **mezlocillin,** neutropenia (CR) 112; **minoxidil,** pericarditis (L) 763; **molindone,** hepatotoxicity (CR) 744; **netilmicin,** ototoxicity (ab) 455; **nitrofurantoin,** review (DIR) 540; **noninstitutionalized elderly,** (G) 766; **pentamidine,** sciatic nerve damage (L) 762; **phenytoin,** erythema multiforme (CR) 114; **piperacillin,** neutropenia (CR) 112; **promethazine,** pediatrics, respiratory depression (ab) 445; **propylthiouracil,** hepatitis (CR) 740; **ranitidine,** arthritis (CR) 201; **thiethylperazine,** dystonia (CR) 550; **ticlopidine,** hemorrhage (RPR) 673; **timolol,** ophthalmic solution (DIR) 85; **tobramycin,** ototoxicity (ab) 455; **tolmetin,** urticaria, angioedema (L) 479; **triazolam,** CNS toxicity (CR) 666; **vancomycin,** nephrotoxicity (DIAS) 907
Dugan, William M. (coauthor) see **Parashos, Peter J.,** 139
DuKart, Gary (author) Comment on Mitoxantrone (O) 216
Durrence, C. Wendell (coauthor) see **Nix, David E.,** 299
Dysmenorrhea, primary, fenoprofen (ab) 445

E

Earp, Colleen M. (author) The Lack of Inactivation of Tobramycin by Cefazolin, Cefamandole, and Moxalactam In Vitro (RPR) 677
Echinomycin, phase I evaluation (ab) 457
Economics, cost-benefit analysis, theophylline assays (RPR) 380
Editorials, see also **An Opinion; Hutchinson, Richard A., Hatoum, Hind T.,** and **Witte, Kenneth W.,** Long-Term Survival Strategy for the Pharmacy Profession, 655; **McLeod, Donald C.,** Progress of Clinical Pharmacy In Europe—1985 Update, 320, Residency Training: Pharmacy's Rate-Limiting Step to Clinical Competency, 60; **Nahata, Milap C.,** Handwashing Prevents Infection, 738; **Rapp, Robert P.,** Hospital Intravenous Drug Administration in the Era of Prospective Payment, 146; **Whitney, Harvey A.K., Jr.,** An Official Journal for the American College of Clinical Pharmacy, 920
Education, inservice, geriatrics (G) 483; medical, Pharm.D. faculty (L) 948; pharmaceutical, clerkships (L) 481, creativity (A) 590, Pharm.D. vs. B.S. (L) 950, veterinary clinics (RPR) 315
Education and Research News (NC), California CE Change, 615; Cancer Control Science Associates Program, 616; Cardiology Award Deadline Set, 616; Chemotherapy of Spinal Cord Cancers, 412; New Research Bibliographies Offered, 332; Post-Discharge Care May Reduce Hospital Readmissions, 239; Tests of New Lung Cancer Treatment, 615; Verapamil-Theophylline Interaction to be Studied, 332
Education News (NC), Computer Center to be Established, 159
Educational programs see **Meetings/Educational Programs**
Edwards, David J. (coauthor) see **Bach, David S.,** 446
Eggleston, S. Mark (author) Jaundice Associated with Cephalosporin Therapy (CR) 553
Ehrlich, Donald W. (coauthor) see **Bhatia, Subhash C.,** 744
Einarson, Thomas R. (author) Gout-Like Arthritis Following Cimetidine and Ranitidine (CR) 201
Eisen, Henry (coauthor) see **Barletta, Michael A.,** 764
Elderly, falling (G) 142
Elenbaas, Julia K. (author) The Effect of In-Line Filtration on Tobramycin Delivery (RPR) 122; (coauthor) see **Forrence, Elizabeth A.,** 587
Elenbaas, Robert M. (author) Definition of Clinical Pharmacy as a Specialty in Clinical Practice (O) 149; (author) Subcutaneous Epinephrine vs. Nebulized Metaproterenol in Acute Asthma (RPR) 567; (coauthor) see **Elenbaas, Julia K.,** 122; Astra Clinical Pharmacy Research Award (NC) 792
Ellis, E. (coauthor) see **Vaughan, Leigh,** 452
Ellis, Michael D. (author) book review, 846
Ellis, Robert F. (coauthor) see **Self, Timothy H.,** 749
Engle, Janet P. (author) Mixing Local Anesthetics to Increase Efficacy (DIAS) 663
Ensure, colonoscopy preparation (CTF) 602
Ephedrine, diphenhydramine, prednisone, high-risk radiol-

ogy (CTF) 490
Epinephrine, acute asthma (RPR) 567; cardiopulmonary resuscitation (ab) 460; compared with metaproterenol (RPR) 567; pH, cardiac arrest (ab) 449
Ergotamine, compared with naproxen, migraine (CTF) 952
Erkan, N.V. (coauthor) see **Gilman, Jamie T.,** 445
Erythromycin, compared with tetracycline, resistance (CTF) 952; interaction, theophylline (CTF) 152; oral, colon surgery (ab) 446
Esmolol, supraventricular tachycardia (ab) 446
Ethanol, hypoglycemia (L) 480
Ethinylestradiol, postcoital contraception (CTF) 603
Etoposide, high performance liquid chromatography detection (ab) 449
Evans, William E. (coauthor) see **Abdelfathah, E.,** 456; (coauthor) see **Christensen, M.L.,** 467; (coauthor) see **Crom, William R.,** 467; (coauthor) see **Elenbaas, Robert M.,** 149; (coauthor) see **Teresi, Mary E.,** 466
Evening primrose, premenstrual syndrome (A) 717
Eye, antimicrobial therapy (A) 642

F

Fab fragments see **Digoxin-specific antibody fragments,** 867
Fabri, Peter J. (coauthor) see **Mirtallo, Jay M.,** 464
Fabrizio, Patricia J. (author) Drugs Causing Toxic Epidermal Necrolysis (DIAS) 733
Facher, Gil (coauthor) see **Bayliff, Charles D.,** 307
Faculty, Pharm.D., colleges of medicine (L) 948
Family practice, prescribing patterns (RPR) 205
Fanikos, John R. (coauthor) see **Powell, Stephen H.,** 57
Farchione, Louis A. (author) Comment: Extended Half-life, Second-Generation Cephalosporins in Surgical Prophylaxis (L) 842
Farringer, John A. (author) Quinidine and 3-Hydroxyquinidine Levels during Initiation of Anticonvulsant Therapy and after Chronic Anticonvulsant Administration (ab) 461; (coauthor) see **Beck, Diane E.,** 469
Fat emulsion, adverse reaction incidence (CTF) 867; 20%, nitrogen balance (CTF) 405
FDA News (NC), Antiemetic Approved, 695; Chelation Therapy Warning, 695; Older Drugs to be Included in FDA's Adverse Drug Reaction Reporting, 503; Regulations Approved for New Drugs, 503
Feldman, Ross D. (coauthor) see **Park, Glen D.,** 447, 937
Fellowships, pharmacy (A) 219; postgraduate, pharmacy (A) 57
Fellowships and Residencies, California, University of Southern California, 154; **Colorado,** Denver Veterans Administration Medical Center, 409, 954; **Connecticut,** Hartford Hospital, 954; **Florida,** University of Florida, 154, 230, 496, 611; **Georgia,** Emory University Hospital, 871, 955, Mercer University, 154, 229, University of Georgia, 229, 955; **Idaho,** Boise Veterans Administration Medical Center, 783; **Iowa,** University of Iowa, 689; **Maryland,** Maryland Poison Center, 75, University of Maryland, 870; **Massachusetts,** Brigham and Women's Hospital, 871, 954, Massachusetts General Hospital, 154; **Michigan,** University of Michigan, 871; **Minnesota,** Hennepin County Medical Center, 72; **Missouri,** University of Missouri-Kansas City, 72, 955; **Nebraska,** Creighton University, 870, 955; **New Jersey,** Middlesex General-University Hospital, 154, Rutgers University, 154; **New York,** Montefiore Medical Center, 614; **North Carolina,** University of North Carolina, 956; **Ohio,** Case Western Reserve University, 870, The Ohio State University, 74, 78-, 872, The Ohio State University Hospitals, 229; **Pennsylvania,** Hamot Medical Center, 72, 870, 954, Philadelphia College of Pharmacy and Science, 72; **Rhode Island,** Rhode Island Hospital, 957; **Texas,** University of Texas, 871, University of Texas Health Science Center, 229, Veterans Administration Medical Center, 409; **Wisconsin,** Madison General Hospital, 72
Fendler, Kermit J. (author) Author's Reply: Drug Bulletins and Prescribing (L) 319
Fenfluramine, autistics (CTF) 325, bulimia (CTF) 686
Fenoprofen, compared with aspirin, dysmenorrhea (ab) 445
Fenster, Paul E. (coauthor) see **Nolan, Paul E.,** 463
Fentanyl, cardiac surgery (CTF) 324
Ferguson, Roger K. (coauthor) see **Conner, Dale P.,** 453; (coauthor) see **Mojaverian, Parviz,** 454; (coauthor) see **Rocci, Mario L.,** 453; (coauthor) see **Vlasses, Peter H.,** 454, 581
Ferraro, Joseph M (author) Sucralfate Suspension for Mouth Ulcers (L) 480
Ferry, D.G. (coauthor) see **Cate, E.W.,** 465
Fetner, Harriet H. (coauthor) see **Batey, Sharyn R.,** 844
Fieldman, A. (coauthor) see **Chow, Moses Sing Sum,** 460
Finley, Rebecca S. (author) Cisplatin Nephrotoxicity: A Summary of Preventative Interventions (OT) 362; (coauthor) see **Fortner, Clarence J.,** 21
Fiscella, Richard G. (coauthor) see **Lesar, Timothy S.,** 642
Fischer, James H. (author) Effect of Meals on the Absorption of Enteric-Coated Valproic Acid (ab) 460; (coauthor) see **West, Dennis P.,** 464
Fischer, John (author) Ranitidine and Warfarin Interaction (DIAS) 664
Flecainide, adverse reactions (FF) 703; drug interactions (FF) 705; evaluation (FF) 703; pharmacokinetics (FF) 704
Fletcher, Courtney V. (author) Continuous Infusion of High-Dose Acyclovir for Serious Viral Infections (ab) 466; (author) Evaluation of Oral Acyclovir Therapy (FF) 518; (coauthor) see **Brundage, Diane M.,** 453
Flint, N.B. (coauthor) see **Comstock, Thomas J.,** 465
Fludarabine, intraperitoneal, pharmacokinetics (ab) 457
Fluphenazine, priapism (CTF) 867
Flurazepam, central nervous system symptoms (RPR) 38
Fogel, Rita S. (coauthor) see **Markowitz, Jeffrey S.,** 481
Fong, Phillip A. (author) Using Journals for Drug Information Requests (L) 765; (coauthor) see **Frost, R. Wayne,** 481
Food and Drug Administration see **FDA**
Foreign Abstractors, 4, 82, 164, 242, 335, 414, 508, 622, 698, 794, 882
Formulary Forum, Amoxicillin-Potassium Clavulanate: A Novel Beta-Lactamase Inhibitor, 415; Aztreonam—An Overview, 171; Buspirone: A New Type of Anxiolytic, 624; Ceftazidime Review, 509; Ceftriaxone: A Third-Generation Cephalosporin, 900; Evaluation of Oral Acyclovir Therapy, 518; Flecainide: A New Class Ic Antiarrhythmic, 703; Imipenem/Cilastatin: The First Carbapenem Antibiotic, 894; Iohexol and Iopamidol: Second-Generation Nonionic Radiographic Contrast Media, 525; Monooctanoin use for Gallstone Dissolution, 708; Pentoxifylline: A New Agent For Intermittent Claudication, 345; Pimozide: Use in Tourette's Syndrome, 421; Terfenadine, A Nonsedating Antihistamine, 812; Tocainide: A New Oral Antiarrhythmic, 514
Forney, Stuart D. (coauthor) see **Scalley, Robert D.,** 315
Forrence, Elizabeth A. (author) Comment: Transdermal Nitroglycerin (L) 587
Fortner, Clarence L. (author) Combination Antiemetic Therapy in the Control of Chemotherapy-Induced Emesis (OC) 21; (coauthor) see **Finley, Rebecca S.,** 362
Foster, Todd P. (coauthor) see **Miller, Donald P.,** 140
Foulks, Gary N. (author) book review, 599
Fracasso, J.E. (coauthor) see **Schentag, Jerome J.,** 462
Frankel, Eric H. (coauthor) see **Bodendorfer, Thomas W.,** 827
Fraser, D.G. (coauthor) see **Townsend, Raymond J.,** 447
Fraser, Gilles L. (author) Evaluation of High-Dose Tobramycin-Carbenicillin Therapy in Pseudomonal Infections in Cystic Fibrosis (RPR) 757
Fried, T. (coauthor) see **Talbert, Robert L.,** 448
Friedman, Paul A. (coauthor) see **Kaul, Alan F.,** 369
Frigoletto, Fredric D., Jr. (coauthor) see **Kaul, Alan F.,** 369
Frolicher, D. (coauthor) see **Dasta, Joseph F.,** 448
Frost, Gary L. (coauthor) see **Elenbaas, Robert M.,** 567
Frost, R. Wayne (author) Comparing Clerkships: Single-Degree Pharm.D., vs. Post-B.S. Pharm.D. Programs (L) 481
Fruncillo, Richard J. (coauthor) see **Rocci, Mario L., Jr.,** 453, 831
Fuentes, J.L. (coauthor) see **Jimenez-Alonso, J.,** 477
Fulp, Sam R. (coauthor) see **Bodendorfer, Thomas W.,** 827
Furnell, Malcom M. (author) The Effect of Sulindac on Lithium Therapy (CR) 374
Furosemide, pharmacokinetics (ab) 448

G

Gagnon, Jean Paul (coauthor) see **Osterhaus, Jane T.,** 134
Gainer, R. Brooks (coauthor) see **Smego, Raymond A.,** 461
Gal, Peter (coauthor) see **Gilman, Jamie T.,** 445
Garabedian-Ruffalo, Susan M. (author) Adverse Effects Secondary to Baclofen Withdrawal (CR) 304; (coauthor) see **Gray, David R.,** 575
Garcia, Jacinto Garcia (coauthor) see **Barbero, Julita Rodriguez,** 394
Garnett, William R. (coauthor) see **Comstock, Thomas J.,** 465
Garrard, Elwyn (coauthor) see **Sargenti, Christine,** 380
Garrett, Edward R. (author) Is it Possible to Teach Scientific Creativity in the Pharmaceutical Sciences? Anecdotes and Memorabilia (A) 590
Garty, Ben-Zion (author) Hepatitis Associated with Propylthiouracil Treatment (CR) 740
Garty, Moshe (coauthor) see **Lustig, Shamir,** 763
Gaspard, J.J. (coauthor) see **Bussey, Henry I.,** 458
General News (NC), AMVETS Donates to Geriatric Program, 879; Computerized Drug Dosage, 695; Drug Interaction Computer Program, 160; International Pharmacy-Nursing Conference, 79; New Statistics Software Package, 504; Nurses Work to Overcome Prescription Noncompliance, 504; Nutritional Supplements Shorten Hospital Stays of Burn Patients, 160; Pharmacokinetic Workshop, 962; Prescription Drug Database Expanded, 504; Swedish Hospital Pharmacists Tour Clinical Pharmacy Facilities in U.S., 962
Gentamicin, carbenicillin, compared with ceftazidime, cystic fibrosis (CTF) 867; clindamycin, compared with imipenem/cilastatin (ab) 455, 466; gram-negative infections (RPR) 309; pharmacokinetics (ab) 469
George, D. (coauthor) see **Massanari, Marc,** 462
Gerbino, Philip P. (coauthor) see **Elenbaas, Robert M.,** 149
Geriatrics, antianxiety agents (RPR) 37; inservice education (G) 483; medication-related problems (G) 766; misperceptions of drug purposes (ab) 452; phenytoin dosing (L) 584
Geriatrics and Gerontology, Factors Associated with the Elderly Falling in Intermediate Care Facilities, 142; Inservice Teaching and Adverse Drug Reactions in a Nursing Home, 483; New Dimensions And Opportunity, 399; Potential Medication-Related Problems in Noninstitutionalized Elderly, 766
Gill, Barbara (coauthor) see **Howard, Patricia,** 763
Gilman, Jamie T. (author) Factors Influencing Theophylline Disposition in 179 Newborns (ab) 445
Gilman, Miles E. (author) Safety and Efficacy of Low Dose Amiodarone Therapy in Patients with Left Ventricular Dysfunction; Preliminary Data (ab) 446
Gilman, Thomas M. (author) Pharmacokinetics of Sulfamethoxazole during Trimethoprim/Sulfamethoxazole Treatment of *Pneumocystis cariini* Pneumonia in Patients with Acquired Immune Deficiency Syndrome (ab) 453; (coauthor) see **Hurst, Agneta K.,** 469
Gitoxin, compared with digoxin, cardiac failure (L) 945
Glazer, Howard M. (coauthor) see **Shimp, Leslie A.,** 766
Glazier, Howard S. (author) A Cost Comparison of the Treatment of Surgical Infections with Imipenem/Cilastatin versus the Combination of Clindamycin and Gentamicin (ab) 466
Glucose, beta-blockers (A) 246; blood, home monitoring (CTF) 151
Glyburide, pharmacokinetics, effect of cimetidine and ranitidine (ab) 461
Glycerin, intracranial hypertension (L) 56; metrizamide, phenol, refractory spasticity (CTF) 952
Goehrs, Homer R. (coauthor) see **Sagraves, Rosalie,** 55
Goetsch, Donald W. (author) Are Pharmacy Journals Negligent? (L) 394
Goldberg, Emanuel (author) Vasodilator vs. Direct Inotropic Effect of Milrinone: Evaluation Using an Animal Model of Left Ventricular Failure (ab) 468
Goldberg, Leon I., honorary membership, Academy of Pharmaceutical Sciences (NC) 80
Goldberg, Mark J. (coauthor) see **Park, Glen D.,** 447, 937
Goldberger, Suanne P. (coauthor) see **Green, Laurence,** 427
Goldenberg, Robin I. (author) Pitfalls in the Delivery of Outpatient Intravenous Therapy (S) 293
Goldstein, Jill E. (coauthor) see **Einarson, Thomas R.,** 201
Golightly, Larry K. (author) Exercise and Beta-Blocking Agents (TC) 302; (coeditor) see **Smolinske, Susan C.**
Gollamudi, R. (author) book review, 226
Gonzalez, Edgar R. (author) Effect of pH on the Ability of Epinephrine, Atropine Sulfate, and Calcium Chloride to Alter the Rhythm from Asystole during Cardiac Arrest in Humans (ab) 449; (author) Prophylaxis of Stress Ulcers: Antacid Titration vs. Histamine$_2$-Receptor Blockade (DSP) 807
Goodner, Susan M. (coauthor) see **True, Bev Lorraine,** 714
Gordon, Martin N. (coauthor) see **Tao, Glen K.,** 548
Gossypol, male contraceptive (CTF) 152
Gotz, Vincent P. (author) Effect of Filtering Amphotericin B Infusions on the Incidence and Severity of Phlebitis and Selected Adverse Reactions (RPR) 436; (author) Evaluation of Tetracycline on Theophylline Disposition in Patients with Chronic Obstructive Pulmonary Disease (ab) 463; (coauthor) see **Massey, Kenneth L.,** 5; (coauthor) see **Parish, Roy C.,** 199
Gower, W. (coauthor) see **Mirtallo, Jay M.,** 464
Grabenstein, John D. (author) Comment: Sources of Parenteral Glycerol used in Intracranial Hypertension (L) 56; (author) Comment: Cyclosporine and Vaccination (L) 679
Grasela, Dennis M. (coauthor) see **Rocci, Mario L., Jr.,** 831
Gray, David R. (author) Author's Reply: Anticoagulation Clinic Cost Justification (L) 947; (author) Cost-Justification of a Clinical Pharmacist-Managed Anticoagulation Clinic (RPR) 575
Gray, J. (coauthor) see **Venkataramanan, Raman,** 451
Gray, R. (coauthor) see **MacCosbe, Paul E.,** 446
Green, A.A. (coauthor) see **Crom, William R.,** 467
Green, Jeffrey A. (author) Author's Reply: Indomethacin Sustained-Release (L) 682; (coauthor) see **Mendel, Stephen,** 946
Green, Laurence (author) Prolonged Elimination of Piperacillin in a Patient with Renal and Liver Failure (CR) 427
Green, Paul J. (coauthor) see **Cummings, Doyle M.,** 467; (coauthor) see **Mojaverian, Parviz,** 454
Greenblatt, David J. (author) Comment: Triazolam—Cimetidine Reaction (L) 679
Griffith, Bartley P. (coauthor) see **Howrie, Denise L.,** 425
Grimes, Gilbert R. (coauthor) see **Fraser, Gilles L.,** 757
Griseofulvin, compared with ketoconazole, dermatophytosis (CTF) 952
Grove, William R. (coauthor) see **Finley, Rebecca S.,** 362; (coauthor) see **Fortner, Clarence L.,** 21
Grund, Vernon R. (author) book review, 403
Grysiak, Deborah L. (coauthor) see **Weber, Robert J.,** 13
Guanabenz, compared with hydrochlorothiazide (A) 632; opiate withdrawal (CR) 32
Guar gum, postprandial blood glucose (CTF) 952
Guay, David R.P. (author) book review, 683
Guenzet, Jacques (coauthor) see **Laurent, Dominique,** 584
Guharoy, Sudip (author) Comment: Pharmacy in India (L) 765
Gumbchir, Ashok K. (coauthor) see **Fendler, Kermit J.,** 319
Gutschi, L. Maria (author) Sciatic Nerve Damage Associated with Pentamidine (L) 762
Gutterman, Elane M. (coauthor) see **Markowitz, Jeffrey S.,** 481

H

Haas, Curtis E. (author) Comment: Second-Generation Cephalosporins (L) 843
Haimowitz, Azriel (coauthor) see **Goldberg, Emanuel,** 468
Hakala, T.R. (coauthor) see **Ptachcinski, Richard J.,** 450
Hale, William E. (author) Antianxiety Drugs and Central Nervous System Symptoms in an Ambulatory Elderly Population (RPR) 37
Hall, Thomas G. (author) Comment: Aminoglycoside Dosing (L) 396
Haloperidol, conduct disorder (CTF) 68; hyperthermia (L) 211; intensive care unit syndrome (CC) 17
Halothane, anesthetic responses (CTF) 952; status asthmaticus (CR) 307

Halstenson, Charles E. (author) Piperacillin Disposition is not Affected by Concomitant Aminoglycoside Administration (ab) 455; (coauthor) see **Abraham, Paul A.,** 454; (coauthor) see **Heim, Karen L.,** 455; (coauthor) see **Matzke, Gary R.,** 455
Hamilton, Stephen F. (author) Circulatory Effects of Sulfinalol during Exercise (ab) 451
Hansen's disease, dapsone, compliance (ab) 464
Hansten, Philip D. (author) book review, 225
Hanyok, J.J. (author) Lorcainide for the Treatment of Drug-Resistant Ventricular Tachycardia: Electrophysiologic and Clinical Results (ab) 459; (author) Prediction of Steady-State Trough Plasma Quinidine Concentrations Following Administration of a Sustained-Release Preparation (ab) 459
Harada, Don T. (coauthor) see **Tao, Glen K.,** 548
Hardesty, Robert J. (coauthor) see **Howrie, Denise L.,** 425
Harford, A.H. (coauthor) see **Comstock, Thomas J.,** 465
Harman, E. (coauthor) see **Hill, Malcom,** 464
Harris, David J. (author) book review, 600
Harris, H.H. (coauthor) see **Rocci, Mario L.,** 453
Harris, S.C. (coauthor) see **Watson, William A.,** 458
Harrison, Sandra A. (author) Hallucinations after Preoperative Baclofen Discontinuation in Spinal Cord Injury Patients (CR) 747
Hart, Jacob (coauthor) see **Djaldetti, Meir,** 583
Hart, Linda L. (author) Progesterone Suppositories in Premenstrual Syndrome (DIAS) 297; (coauthor) see **Kreter, Bruce,** 300; (coauthor) see **Leong, Patricia,** 909; (coauthor) see **Noud, Mary,** 732; (coauthor) see **Tom, Michael,** 185; (editor) DIAS Rounds, 25, 185, 297, 359, 662, 732, 907
Hartshorn, Edward A. (author) book review, 599
Hasegawa, Guy R. (author) Tocainide: A New Oral Antiarrhythmic (FF) 514
Hassan, Erkan (author) Hemodynamic Effects of Bumetanide in Seriously Ill Patients (ab) 453; (coauthor) see **Wiser, Thomas H.,** 397
Hassett, James M. (coauthor) see **Slaughter, Richard L.,** 799
Hatoum, Hind T. (coauthor) see **Hutchinson, Richard A.,** 655; (coauthor) see **Witte, Kenneth W.,** 452
Hau, T. (coauthor) see **Danziger, Larry H.,** 455
Hawkins, D.W. (coauthor) see **Bussey, Henry I.,** 458
Hayes, J. Michael (coauthor) see **Carter, Charles A.,** 812
Hays, Dennis P. (author) book review, 404, 683; (author) Phenytoin Clearance by Continuous Ambulatory Peritoneal Dialysis (CR) 429
Health care, cost-containment (S) 291; home, infusion services (S) 282; intravenous antibiotics (ab) 461
Heflin, Kathy C. (author) Thyroid Labeling Error (L) 945
Heim, Karen L. (author) The Effect of Hemodialysis on Piperacillin Pharmacokinetics (ab) 455; (coauthor) see **Halstenson, Charles E.,** 455
Hekster, Y.A. (coauthor) see **Dirksen, M.S.C.,** 945
Helling, Dennis K. (coauthor) see **Semla, T.P.,** 452
Hemiacidrin, hypermagnesemia (CTF) 228
Hendeles, Leslie (author) Measurement of Tobramycin Concentrations in Saliva (RPR) 378; (coauthor) see **Hill, Malcolm,** 464; (coauthor) see **Massanari, Marc,** 462; (coauthor) see **Massey, Ken,** 462; (coauthor) see **Milavetz, Gary,** 458
Henderson, R.P. (coauthor) see **Lander, Roger D.,** 450
Henman, Martin (author) Comment: Education in Spain, 319
Heparin, calcium, deep vein thrombosis prophylaxis (CTF) 867; dihydroergotamine, vascular spasm and gangrene (CTF) 406; hyperkalemia (CTF) 867
Herbst, John J. (coauthor) see **Bosso, John A.,** 52
Herfindal, Eric T. (author) Impact of Clinical Pharmacy Services on Prescribing on a Cardiothoracic/Vascular Surgical Unit (RPR) 440
Hersh, C.B. (coauthor) see **Gilman, Jamie T.,** 445
Hersh, M.R. (author) High Performance Liquid Chromatographic Assay for Etoposide (VP-16) using Ultraviolet Detection (ab) 449
Heseltine, P.N.R. (coauthor) see **Gilman, Thomas M.,** 453
Hewett, J.E. (coauthor) see **Beach, C.L.,** 451
Hickman catheters, flushing (CTF) 952
Higuchi, Takeru, Honorary Fellow of the Pharmaceutical Society of Great Britain (NC) 880
Hill, Malcolm (author) The Effect of Increasing Doses of Inhaled Verapamil on Airway Reactivity to Methacholine in Mild Asthmatics: A Paradoxical Response (ab) 464; (coauthor) see **Hendeles, Leslie,** 378
Hilleman, Daniel E. (author) Lidocaine-Induced Second-Degree Mobitz Type II Heart Block (CR) 669
Histamine, antagonists, intensive care unit syndrome (CC) 15
Hittel, William P. (author) Kinetic Dosing Computer Support (L) 141
Hoff, J. (coauthor) see **MacCosbe, Paul E.,** 446
Hoffer, Susan (coauthor) see **Cersosimo, Robert J.,** 118
Homma, Shunichi (coauthor) see **Ameer, Barbara,** 457
Hong, Waun Ki (coauthor) see **Cersosimo, Robert J.,** 921
Hopefl, Alan W. (author) Aztreonam—An Overview (FF) 171
Horn, John R. (author) Evaluation of a Digoxin Pharmacokinetic Monitoring Service in a Community Hospital (RPR) 45; **Mills, Gregory A.,** 246
Horner, Philip (coauthor) see **Ponte, Charles D.,** 139
Howard, Patricia (author) Cyclosporine—Rifampin Drug Interaction (L) 763
Howrie, Denise L. (author) Anaphylactoid Reactions Associated with Parenteral Cyclosporine use: Possible Role of Cremophor El (CR) 425; (coauthor) see **Burckart, Gilbert J.,** 450
Hryhorczyk, L. (coauthor) see **Berchou, Richard C.,** 449
Huckendubier Stephenson, Susan E. (coauthor) see **Bosso, John A.,** 52
Huggins, W.F. (coauthor) see **Markiewicz, Michael A.,** 447
Humphrey, Elizabeth A. (author) book review, 226
Hunt, Stephanie A. (author) Analysis of a Peer-Conducted Quality Assurance Program for Pharmacokinetic Dosing Services (ab) 465
Hurst, Agneta K. (author) Population Pharmacokinetics of Gentamicin in Internal Medicine Patients (ab) 469
Hutchinson, Richard A. (author) Long-Term Survival Strategy for the Pharmacy Profession (E) 655
Hwang, P.T.R (coauthor) see **Straughn, Arthur B.,** 461
Hydralazine, congestive heart failure (CTF) 227; glomerulonephritis (CTF) 406
Hydrochlorothiazide, amiloride, nephrogenic diabetes insipidus (CTF) 602
Hydrogen ion concentration, atropine sulfate, cardiac arrest (ab) 449; calcium chloride, cardiac arrest (ab) 449; epinephrine, cardiac arrest (ab) 449
Hydroxychloroquin, breast milk concentration (CTF) 953
3-Hydroxyquinidine, effect of anticonvulsants (ab) 461
7-Hydroxymethotrexate, plasma protein binding (ab) 456
Hydroxyurea, polycythemia vera (CTF) 324
Hypertension, management (A) 629
Hypokalemia, management (A) 176

I

Iafrate, R. Peter (coauthor) see **Hendeles, Leslie,** 379
Iatropoulos, Michael J. (coauthor) see **DuKart, Gary,** 216
Ibuprofen, compared with aspirin (CTF) 406; inflammatory acne (CTF) 405; phenytoin pharmacokinetics (ab) 447; ventricular septal rupture (CTF) 953
Idoxuridine, herpes labialis (CTF) 67
Iglesias, T. (coauthor) see **Hurst, Agneta K.,** 469
Imipenem/cilastatin, adverse reactions (FF) 896; bacteremia (CTF) 952; compared with gentamicin, tobramycin (ab) 455; compared with clindamycin, gentamicin (ab) 466; efficacy (L) 840; evaluation (FF) 894; pharmacokinetics (ab) 467, (FF) 895
Imipramine, panic attacks (ab) 449; plasma levels (CTF) 603; stress incontinence (CTF) 325
Immunization, pertussis (TC) 729
Immunosuppressives, sarcoidosis (DIAS) 909
India, combination drugs (L) 319; pharmacy practice (L) 765
Indomethacin, cataract surgery (CTF) 491; intestinal perforations (CTF) 603; lithium-induced polyuria (CTF) 686; sustained-release (L) 681
Infections, ophthalmic (A) 642
Information, drug see **Drug Information**
Insulin, glyburide, combination therapy (CTF) 405; human, desensitization (CR) 827
Intensive care unit syndrome, review (CC) 13
Interferons, alpha, adverse reactions (DSP) 888; evaluation (DSP) 887; pharmacokinetics (DSP) 888
Intermittent claudication, pentoxifylline (FF) 345
International Reports, Pharmaceutical Services at Sint Radboud Hospital, 859
Intravenous therapy, outpatient (S) 293
Investigational Drug Information, Ipratropium Bromide, 5
Iohexol, adverse reactions (FF) 526; evaluation (FF) 525; pharmacokinetics (FF) 527
Iopamidol, adverse reactions (FF) 526; evaluation (FF) 525; pharmacokinetics (FF) 527
Ipratropium bromide, evaluation (ID) 5; pharmacokinetics (ID) 6
Isoproterenol, aerosol, penny aspiration (CTF) 68; panic attacks (ab) 449
Isosorbide dinitrate, myocardial infarction (CTF) 67
Isotretinoin, arthritis (CTF) 152; galactorrhea (CTF) 686
Italy, antiepileptic drug monitoring (TM) 913
Iwatsubo, Janet (author) Prevention of Chymopapain Anaphylaxis (DIAS) 26
Iwatsuki, S. (coauthor) see **Burckart, Gilbert J.,** 450

J

Jackson, Eric A. (coauthor) see **Jackson, Max G.,** 205
Jackson, M. (author) Comment: Ineffectiveness of Droperidol as Antiemetic (L) 841
Jackson, Max G. (author) Family Practice Residents' Prescribing Patterns (RPR) 205
Janicke, D.M. (coauthor) see **Morse, Gene D.,** 469
Jayashankar, J. (coauthor) see **Zarowitz, Barbara J.M.,** 459
Jeffrey, Louis R. (coauthor) see **Fabrizio, Patricia J.,** 733
Jelliffe, R.W. (coauthor) see **Hurst, Agneta K.,** 469
Jenne, J. (coauthor) see **Vaughan, Leigh,** 452
Jimenez-Alonso, J. (author) Cyclophosphamide Failure in Takayasu's Disease (L) 477
Jimenez-Pereperez, J.A. (coauthor) see **Jimenez-Alonso, J.,** 477
Jinks, Martin J. (author) book review, 153
Johnson, D.W. (coauthor) see **Matzke, Gary R.,** 455
Johnson, George F. (coauthor) see **Park, Glen D.,** 447, 937
Johnson, Matthew H. (coauthor) see **Hunt, Stephanie A.,** 465
Johnson, R. (coauthor) see **Gilman, Thomas M.,** 453
Jones, D. (coauthor) see **Burckart, Gilbert J.,** 450
Jozefczyk, Kenneth G., appointments at Medical University of South Carolina (NC) 616
Jue, Sandra G. (author) Inservice Teaching and Adverse Drug Reactions in a Nursing Home (G) 483
Juffe, Alberto (coauthor) see **Criado, Antonio,** 673
Juhl, Randy P. (coauthor) see **Kubacka, Renee T.,** 461
Jusko, William J. (author) book review, 773; (coauthor) see **Carson, Stanley W.,** 454
Jutrin, Itzhak (coauthor) see **Lishner, Michael,** 433

K

Kamper, Claudia A. (coauthor) see **Phelps, Stephanie J.,** 466
Kaul, Alan F. (author) Postgraduate Pharmacy Fellowships (1984-85) (A) 219; (author) The Management of Preterm Labor with the Calcium Channel-Blocking Agent Nifedipine Combined with the Beta-Mimetic Terbutaline (CR) 369; (coauthor) see **Osathanondh, Rapin,** 445; (coauthor) see **Powell, Stephen H.,** 57
Kauli, Rivka (coauthor) see **Garty, Ben-Zion,** 740
Kawada, Tom K. (author) Iohexol and Iopamidol: Second-Generation Nonionic Radiographic Contrast Media (FF) 525
Kay, Bruce G. (coauthor) see **Markowitz, Jeffrey S.,** 481
Keane, W.F. (coauthor) see **Abraham, Paul A.,** 454; (coauthor) see **Matzke, Gary R.,** 455
Kelly, Kim L. (coauthor) see **Elenbaas, Robert M.,** 149
Kennedy, M.S. (coauthor) see **Yee, Gary C.,** 445
Kerner, N. (coauthor) see **Bach, David S.,** 446
Kershner, Robert M. (coauthor) see **Munroe, Wendy P.,** 85
Ketamine, amnesia (CTF) 324
Ketoconazole, compared with griseofulvin, dermatophytosis (CTF) 952; fungal toenail infection (CTF) 227; prostate cancer (CTF) 68; seborrheic dermatitis (CTF) 866; small-cell lung cancer (CTF) 776; tinea versicolor (CTF) 405
Khanderia, Ujjaini (author) Recurrent Dystonic Reactions Induced by Thiethylperazine (CR) 550
Ki Hong, Waun (coauthor) see **Cersosimo, Robert J.,** 118
Kidney stones, therapy (DSP) 530
Kinnard, William J., Jr. (coauthor) see **Elenbaas, Robert M.,** 149
Kirby, M.G. (coauthor) see **Dasta, Joseph F.,** 448
Kirkwood, Craig F. (author) Neutropenia Associated with Mezlocillin and Piperacillin (CR) 112
Kishi, Donald T. (coauthor) see **Herfindal, Eric T.,** 440
Klamerus, K.J. (coauthor) see **Witte, Kenneth W.,** 452
Klein, Catherine (coauthor) see **Rhodes, Richard S.,** 556
Kluger, Jeffrey (coauthor) see **Chow, Moses Sing Sum,** 460; (coauthor) see **Hanyok, J.J.,** 459
Knowles, Mark R., academy chairman, American Academy of Health Administration (NC) 412
Koch, John P. (coauthor) see **Bayliff, Charles D.,** 307
Koehl, M. (coauthor) see **Reedy, Michael E.,** 457
Kohout, F.J. (coauthor) see **Semla, T.P.,** 452
Kootsikas, Maria E. (coauthor) see **Tao, Glen K.,** 548
Kopp, Daniel L. (coauthor) see **Armstrong, Edward P.,** 753
Koren, Gideon (author) Comment: Monitoring Pediatric IV Drugs (L) 210
Koyama, Eileen A. (coauthor) see **Spierer, Diane N.,** 762
Kramer, Barnett S. (coauthor) see **Gotz, Vincent P.,** 436
Kramer, Warren (author) Comment: Chymopapain Evaluation (L) 398
Kreter, Bruce (author) Skin Testing for Anergy (DIAS) 300
Kroboth, Patricia D. (coauthor) see **Smith, Randall B.,** 449, 450
Krogg, E.A. (coauthor) see **Nahata, Milap C.,** 445
Kruyer, W.B. (coauthor) see **Lehmann, Craig R.,** 460
Kubacka, Renee T. (author) Influence of Age on Clindamycin Pharmacokinetics (ab) 450; (author) The Effects of Cimetidine and Ranitidine on Glyburide Pharmacokinetics (ab) 461
Kuhn, John G. (author) Phase 1 Evaluation of Echinomycin (ab) 457; (coauthor) see **Salva, Kathryn M.,** 461; (coauthor) see **Schwartz, R.,** 457
Kuhn, Robert J. (author) Netilmicin Pharmacokinetics in Newborn Infants (ab) 445
Kurland, Geoffrey (coauthor) see **Marquardt, Eric D.,** 840

L

Labetalol, compared with bendrofluazide (A) 632; monotherapy (ab) 456
Lactate, panic attacks (ab) 449
Laddu, A.R. (coauthor) see **MacCosbe, Paul E.,** 446
Laizure, S.C. (author) Stability of Bupropion and its Major Metabolites in Human Plasma Under Varying pH and Temperature Storage Conditions (ab) 447
Lake, Kathleen D. (author) Comparison of Vancomycin Serum Concentrations Obtained with Standard vs. Individualized Dosing Regimens (ab) 459; (author) New Drug Therapy for Kidney Stones: A Review of Cellulose Sodium Phosphate, Acetohydroxamic Acid, and Potassium Citrate (DSP) 530
Lalonde, Richard L. (author) Comparison of Results Obtained by High Pressure Liquid Chromatography and Fluorescent Polarization Immunoassay Methods in a Theophylline Pharmacokinetic Study (ab) 449
Lam, Y.W. Francis (author) Clinical Evaluation of Aminoglycoside Nephrotoxicity using the Moore-Smith Nomogram (ab) 451
Lampasona, Victor (author) Vancomycin Dosing in Patients with Varying Degrees of Renal Function—Comparison of Individualized Methods with Nomogram Methods (ab) 465
Lamy, Peter P. (author) New Dimensions and Opportunities (G) 399; (editor) Geriatrics and Gerontology, 142, 399, 483, 766
Lander, Roger D. (author) Pharmacokinetic Comparison of Azlocillin 5 g q8h vs. 4 g q6h in Healthy Volunteers (ab) 450; (coauthor) see **Elenbaas, Julia K.,** 122
Lang, Ruth (coauthor) see **Lishner, Michael,** 433
Lapp, Janet E. (coauthor) see **Marinier, Raymonde L.,** 40
Larijani, Ghassem E. (author) The Influence of Amiodarone on the Pharmacokinetics of Theophylline in Rats (ab) 454
Laron, Zvi (coauthor) see **Garty, Ben-Zion,** 740

Laszekay, George M. (coauthor) see **Kirkwood, Craig F.,** 112
Latimer, P.T. (coauthor) see **Yuen, Geoffrey J.,** 469
Lau, Alan (author) Evaluation of a Potential Drug Interaction Between Sucralfate and Aspirin (ab) 457
Lau, Teresa (author) Vancomycin Nephrotoxicity (DIAS) 907
Laurent, Dominique (author) In Vitro Adsorption of Sodium Phenytoin by Anion Exchange Resin (L) 584
Lawrence, Gene (coauthor) see **Wells, Barbara G.,** 142
LeBel, Marc (author) Serum Bactericidal Activity of Ceftazidime Increased by Netilmicin (RPR) 932
Lee, Marilyn D. (coauthor) see **Self, Timothy H.,** 749
Lee, Mary (author) book review, 321
LeFrock, Jack L. (author) A Comparative Study of Gentamicin and Netilmicin in the Treatment of Gram-Negative Infections (RPR) 309; (coauthor) see **Smith, Bruce R.,** 415
Lehmann, Craig R. (author) Comparison of Sustained-Release Quinidines Given Twice Daily (ab) 460; (author) Quinidine Assays: Enzyme Multiplied Immunoassay Technique vs. High Performance Liquid Chromatography (ab) 460
Lemke, J.H. (coauthor) see **Semla, T.P.,** 452
Leng, Marisa (author) Serum Sickness with Cefaclor (DIAS) 186
Leone, Nello (coauthor) see **Bonati, Maurizio,** 913
Leong, Patricia (author) Immunosuppressives in Sarcoidosis (DIAS) 909
Lesar, Timothy S. (author) Antimicrobial Drug Delivery to the Eye (A) 642
Lesne, Michel L. (coauthor) see **Pellegrin, Patrick,** 945; (coauthor) see **Wallemacq, Pierre E.,** 29
Lester, R. (coauthor) see **MacCosbe, Paul E.,** 446
Letendre, Peter W. (author) The use of methotrexate in Rheumatoid Arthritis (A) 349
Letters, Are Pharmacy Journals Negligent?, 394; Caffeine Citrate: An Alternative to Theophylline for Apnea in Prematurity, 762; Cefmetazole Plasma Levels After Intraincisional Administration, 394;
Comments/Authors' Replies: Aminoglycoside Dosing, 396; Anticoagulation Clinic Cost Justification, 947; Ceforanide Half-Life, 588; Cimetidine Kinetics in Neonate, 588; Combination Drugs in India, 319; Drug Bulletins and Prescribing, 318; Extended Half-Life, Second-Generation Cephalosporins in Surgical Prophylaxis, 842; Guidelines for IV Drugs, 56; Indomethacin Sustained-Release, 681; Monitoring Pediatric IV Drugs, 210;
Comments: Amphotericin B Bladder Irrigations, 587; Antibiotic use in Cystic Fibrosis, 318; Antibiotics in Acute Exacerbations of COAD, 397; Cephalosporins in Surgical Prophylaxis, 586; Chymopapain Evaluation, 398; Cyclosporine and Vaccination, 679; Education in Spain, 319; Exercise and Beta-Blockers, 586; Hypophosphatemia, 398; Ineffectiveness of Droperidol as Antiemetic, 841; Lidocaine Seizures, 680; Neuroleptic Malignant Syndrome, 211; Nitroglycerin IV Tubing Adsorption, 946; Pharm.D. Faculty in Medical Schools, 948; Pharmacy in India, 765; Poisoning Prevention, 210; Revised Treatment of Ulcerative Stomatitis, 139; Second-Generation Cephalosporins, 843; Sources of Parenteral Glycerol used in Intracranial Hypertension, 56; Transdermal Nitroglycerin, 587; Triazolam-Cimetidine Reaction, 679;
Community Pharmacists as Drug Information Advisors, 140; Comparing Clerkships: Single-Degree Pharm.D. vs. Post-B.S. Pharm.D. Programs, 480;
Corrections: Aminoglycoside Dosing, 589; Antibiotics in Cystic Fibrosis, 320; Thiethylperazine-Induced Dystonic Reactions, 682; Tocainide, 682;
Cyclophosphamide Failure in Takaysu's Disease, 477;
Cyclosporine—Rifampin Drug Interaction, 763;
Ethanol-Induced Hypoglycemia from Mouthwash, 480;
Fellowship and Residency Announcements, 586;
Gitoxin—A Challenger for Digoxin?, 945; Haloperidol-Associated Hyperthermia, 211; Imipenem/Cilastatin Efficacy Evaluated, 840; Impact on Perception of Side Effects, 213; In Vitro Adsorption of Sodium Phenytoin by Anion Exchange Resin, 584; Ineffectiveness of Probenecid in Theophylline Kinetics and Excretion, 840; Isosorbide Dinitrate—Disopyramide Phosphate Interaction, 764; Kinetic Dosing Computer Support, 141; Latrinization of the Pharm.D., B.S., P.D. Debate, 950; Objectivity in Drug Therapy, 55; Pefloxacin—Aminophylline Interaction, 945; Pericarditis after Minoxidil Reinstitution, 763; Pharm.D. Faculty in Colleges of Medicine, 948; Pharm.D.: A Prolific Author, 844; Phenytoin Once-Daily Dosing in Geriatric Patients, 584; Possible Reaction with NSAIDs and Tartrazine, 478; Professional Development Degrees, 585; Propranolol's Effect on Phagocytizing Ability of Polymorphonuclears and Monocytes, 583; Psychotropic Medication use in Chronically Mentally Ill Females, 844; Qualitative Differences in Drug Knowledge Among Health Professionals, 481; Reducing Cephalosporin Purchases, 211; Sciatic Nerve Damage Associated with Pentamidine, 762; Streptokinase IV Protocol in Acute MI Patients, 764; Sublingual use of Benzodiazepines, 839; Sucralfate Suspension for Mouth Ulcers, 480; Suspected Procainamide-Induced Angioedema, 139; Thyroid Labeling Error, 945; Tobramycin Levels from Hickman Catheters, 477; Tolmetin in Breast Milk, 55; Tolmetin-Induced Urticaria/Angioedema, 479; Using Journals for Drug Information Requests, 765
Leung, Alexander K.C. (author) Ethanol-Induced Hypoglycemia from Mouthwash (L) 480
Levamisole, idiopathic nephrotic syndrome (CTF) 325
Levin, N. (coauthor) see **Zarowitz, Barbara J.M.,** 459
Levine, R.S. (coauthor) see **Gilman, Jamie T.,** 445
Lewin, Harry M. (coauthor) see **Reitberg, Donald P.,** 125
Lidocaine, compared with cocaine (CTF) 227; heart block (CR) 669; pharmacokinetics, preeclampsia (ab) 456; seizures (CR) 199, (L) 680
Lillard, David (coauthor) see **Wells, Barbara G.,** 142
Linoleic acid, multiple sclerosis (CTF) 324
Lisby, S.M. (coauthor) see **Comstock, Thomas J.,** 465
Lishner, Michael (author) Analgesic Effect of Ceruletide Compared with Pentazocine in Biliary and Renal Colic: A Prospective, Controlled, Double-Blind Study (RPR) 433
Liskow, Barry I. (author) book review, 322, 951
Literature, 69, 153, 225, 321, 403, 488, 599, 683, 773, 845, 951, see **Book Reviews, Books Received**
Lithium, bulimia (CTF) 228; compared with verapamil (CTF) 403; conduct disorder (CTF) 68; interactions (CR) 31; premenstrual syndrome (A) 717; seizures (CTF) 228; sulindac therapy (CR) 374; thrombophlebitis (CTF) 152
Littlefield, Louis C. (coauthor) see **Yuen, Geoffrey J.,** 469
Lloyd, Charles W. (author) Authors' Reply: Cimetidine Kinetics in Neonate (L) 588; (author) The Pharmacokinetics of Cimetidine and Metabolites in a Neonate (CR) 203
Lofexidine, compared with clonidine, essential hypertension (RPR) 928
Lomustine, doxorubicin, compared with cyclophosphamide (CTF) 491; doxorubicin, prostatic carcinoma (CTF) 491
Longe, R. Leon (author) Peripheral Vascular and Lymphatic Systems (PA) 252
Loperamide, acute diarrhea (CTF) 406
Lopez, Julio (coeditor) see **Hart, Linda L.,** 732
Lopez, Larry M. (author) Long-Term Experience with Lofexidine in the Treatment of Mild-to-Moderate Essential Hypertension (RPR) 928
Lorazepam, antiemetic action (CTF) 953; central nervous system symptoms (RPR) 38; chemotherapy-induced emesis (OT) 23; compared with propranolol, neuroleptic-induced akathisia (CTF) 953; intensive care unit syndrome (CC) 16
Lorcainide, ventricular tachycardia (ab) 459
Love, Steven J. (coauthor) see **Reitberg, Donald P.,** 125
Lubin, Ernest (coauthor) see **Garty, Ben-Zion,** 740
Lubner, Maxine (coauthor) see **Markowitz, Jeffrey S.,** 481
Ludden, Thomas M. (coauthor) see **Hersh, M.R.,** 449; (coauthor) see **Talbert, Robert L.,** 456
Lukazewski, A. (coauthor) see **Barbarash, Rick A.,** 466
Lum, Bert L. (author) Doxorubicin: Alteration of Dose Scheduling as a Means of Reducing Cardiotoxicity (OT) 259
Lustig, Shamir (author) Pericarditis after Minoxidil Reinstitution (L) 763
Lyon, James A. (author) book review, 845; (author) Imipenem/Cilastatin: The First Carbapenem Antibiotic (FF) 894
Lyon, Ronald A. (author) Drug Information Roots: The Influence of Education and Training on the Philosophy and Activities of Hospital- and Pharmacy School-Based Drug Information Services (RPR) 390
Lysine, herpes simplex labialis (CTF) 405

M

MacCosbe, Paul E. (author) Antiarrhythmic Efficacy and Safety of Esmolol in Supraventricular Tachycardia (ab) 446
Mackey, R.W. (coauthor) see **Yuen, Geoffrey J.,** 469
MacNay, Kenneth R. (coauthor) see **Einarson, Thomas R.,** 201
Maddux, Michael S. (author) Efficacy of Co-trimoxazole Prophylaxis Against Urinary Tract Infection Following Renal Transplantation (ab) 452
Magnesium citrate, barium enema (CTF) 405
Magnesium sulfate, paralytic ileus (CTF) 603; pheochromocytoma (CTF) 490
Magnesium trisilicate, compared with ranitidine, metoclopramide (CTF) 775
Majerus, Thomas C. (author) book review, 321
Mannitol, compared with phenobarbital (CTF) 405; hypersensitivity (CR) 552
Manoguerra, Anthony S., president-elect, American Association of Poison Control Centers (NC) 80
Maprotiline, seizures (CTF) 776
Marijuana, Emit assays (CTF) 776; intrauterine growth retardation (CTF) 866
Marinier, Raymonde L. (author) Psychotropic Drug use by Women: Demographic, Lifestyle, and Personality Correlates (RPR) 40
Marino, Eduardo L. (coauthor) see **Barbero, Julita Rodriguez,** 394
Markiewicz, Michael A. (author) Prophylactic Efficacy of Cefoxitin versus Cephalothin in Cesarean Section Patients (ab) 447
Markowitz, Jeffrey S. (author) Qualitative Differences in Drug Knowledge Among Health Professionals (L) 481
Marks, Ronald G. (coauthor) see **Hale, William E.,** 37
Marquardt, Eric D. (author) Ineffectiveness of Probenecid in Theophylline Kinetics and Excretion (L) 840
Martin, William J. (coauthor) see **Lloyd, Charles W.,** 203, 588
Massanari, Marc (author) The Effect of Cathartics on Drug Absorption from a Slow-Release Formulation (ab) 462
Massey, Kenneth L. (author) Ipratropium Bromide (ID) 5; (author) Revised Criteria for Monitoring Aminoglycoside Serum Concentrations in Pediatric Patients (ab) 462
Massoud, Neil (coauthor) see **Munzenberger, Paul J.,** 448
Matthews, S. James (coauthor) see **Cersosimo, Robert J.,** 921
Matzke, Gary R. (author) Ototoxicity of Netilmicin vs. Tobramycin in Patients with End-Stage Renal Disease (ab) 455; (coauthor) see **Abraham, Paul A.,** 454; (coauthor) see **Halstenson, Charles E.,** 455; (coauthor) see **Heim, Karen L.,** 455
May, J. Russel (coauthor) see **Nix, David E.,** 300
Mayersohn, Michael (coauthor) see **Nolan, Paul E.,** 463
McAllister, James C., III (author) The Role of the Pharmacist in Home Health Care (S) 282
McCloskey, William W. (coauthor) see **Fabrizio, Patricia J.,** 733
McCoy, Harry G. (coauthor) see **Schaber, Daniel E.,** 572
McGraw, Benjamin F. (author) book review, 321
McGuire, T.R. (coauthor) see **Yee, Gary C.,** 445
McKenney, James M. (author) Alternative Pharmacologic Approaches to the Initial Management of Hypertension (A) 629;
McLeod, Donald C. (author) Pharmaceutica. Services at Sint Radboud Hospital (IR) 859; (author) Progress of Clinical Pharmacy in Europe—1985 Update (E) 320; (author) Residency Training: Pharmacy's Rate-Limiting Step to Clinical Competency (E) 60; (author) Therapeutic Drug Monitoring as a Standard of Care (TM) 473; (editor) Drug Selection Perspectives, 188, 530, 807, 887; (editor Formulary Forum, 171, 345, 415, 421, 509, 514, 518, 525, 624, 703, 708, 812, 894, 900
McNabney, W. Kendall (coauthor) see **Elenbaas, Robert M.,** 567
McNeill, Irene Y. (author) Hypersensitivity Reaction to Mannitol (CR) 552
Mebendazole, insulin requirements (CTF) 67
Medroxyprogestrerone acetate, congenital central hypoventilation syndrome (CTF) 776; seizures (CTF) 151
Meetings/Educational Programs, 76, 160, 229, 327, 409, 497, 608, 689, 782, 870, 976
Mehta, Jawahar L. (coauthor) see **Lopez, Larry M.,** 928
Melikian, A.P. (coauthor) see **Lehmann, Craig, R.,** 460
Mendel, Stephen (author) Comment: Nitroglycerin IV Tubing Adsorption (L) 946
Meperidine, promethazine, chlorpromazine, pediatrics, respiratory depression (ab) 445
Meprobamate, central nervrous system symptoms (RPR) 38
Messenheimer John A., Jr. (coauthor) see **Dalton, Michael J.,** 456, 941
Metaproterenol, acute asthma (RPR) 567; compared with epinephrine (RPR) 567
Methacholine, effect of inhaled verapamil (ab) 464
Methadone, teratogenesis (CTF) 67
Methotrexate, adverse reactions (A) 354; compared with chlorambucil, sarcoidosis (DIAS) 909; compared with cyclosporine, marrow transplantation (CTF) 953; head and neck cancer (CTF) 151; monitoring (CR) 372; monitoring criteria (ab) 467; pharmacokinetics, effect on cisplatin (ab) 467; plasma protein binding (ab) 456; rheumatoid arthritis (A) 349; toxicity (CR) 372
Methyldopa, compared with hydrochlorothiazide (A) 632
Methylergometrine, bronchospasm (CTF) 867
Methylphenidate, attention deficit disorder (CTF) 776; cocaine abuse (CTF) 325; hyperactivity (CTF) 325
Methylprednisolone, adult respiratory distress syndrome (CTF) 776; chemotherapy-induced emesis (OT) 23; lupus nephritis (CTF) 406; premature ventricular contractions (CTF) 952; troleandomycin, asthma (CTF) 686
Metoclopramide, anorexia nervosa (A) 725; aspiration pneumonitis (A) 723; chemotherapy-induced emesis (OT) 23; evaluation (A) 723; failure to thrive (A) 725; gastric bezoars (A) 723; hiccups (A) 726; migraine (A) 727; Parkinson's disease (A) 726; ranitidine, compared with magnesium trisilicate (CTF) 775; tardive dyskinesia (A) 726; vertigo (A) 726
Metoprolol, acute myocardial infarction (CTF) 952; compared with hydrochlorothiazide (A) 632; migraine (CTF) 67
Metrizamide, phenol, glycerin, refractory spasticity (CTF) 952
Metronidazole, cephradine, intraperitoneal abscess (CTF) 685; peripheral neuropathy (CTF) 686; vaginitis (CTF) 151
Metyrapone, Cushing's syndrome (CTF) 490
Meyer, Leeroy E. (author) Impact on Perception of Side Effects (L) 213
Meyer, Marvin C. (coauthor) see **Straughn, Arthur B.,** 461
Meyer, W.H. (coauthor) see **Crom, William R.,** 467
Mezlocillin, neutropenia (CR) 112
Miconazole, fungal keratitis (CTF) 227
Microcomputer, tobramycin pharmacokinetics (ab) 451
Middleton, Bruce (coauthor) see **Wells, Barbara G.,** 142
Mikhail, May N. (author) Using a Hand-Held Spirometer as a Monitoring Tool in Chronic Theophylline Therapy (ab) 447
Milavetz, Gary (author) Theophylline Dosing for Chronic Asthma (ab) 458; (coauthor) see **Vaughn, Leigh,** 452
Milewski, Robert (coauthor) see **Munzenberger, Paul J.,** 448
Millares, Mirta (coauthor) see **Beauchamp, Catherine,** 662; (coauthor) see **Chan, Beatrice,** 735; (coeditor) see **Hart, Linda L.,** 662, 907
Miller, Donald R. (author) Community Pharmacists as Drug Information Advisors (L) 140; (coauthor) see **Letendre, Peter W.,** 349
Miller, Jane L., senior assistant editor, *Clinical Pharmacy* (NC) 880
Miller, Rick (coauthor) see **Ringer, Joseph,** 764
Miller, Russell R., obituary (NC) 962
Miller, William A. (author) In Pursuit of Clinical Pharmacy Excellence (ACCP) 868; (coauthor) see **Elenbaas, Robert M.,** 149
Mills, Gregory A. (author) Beta-Blockers and Glucose Control (A) 246
Milrinone, vasodilator vs. direct inotropic effect (ab) 468
Mineral oil, pneumonia (CTF) 68
Minocycline, compared with diazepam (CTF) 686; nonbacterial prostatitis (CTF) 686
Minoxidil, breast milk (CTF) 491; hair regrowth (CTF) 67; pericarditis (L) 763
Mioduch, James (author) Reducing Cephalosporin Purchases (L) 211

Mirtallo, Jay M. (author) Effect of Parenteral Nutrition on Hepatic Drug Function (ab) 464
Misoprostol, compared with cimetidine, duodenal ulcer (CTF) 866
Mitoxantrone, metastatic breast cancer (CTF) 227
Mitsch, Rita A. (coauthor) see **Calis, Karim A.,** 839
Mitsuoka, J. Chris (coauthor) see **Marquardt, Eric D.,** 840
Mittelman, Moshe (coauthor) see **Djaldetti, Meir,** 583
Miwa, Linda J. (coauthor) see **Iwatsubo, Janet,** 26; (coauthor) see **Wilkins, Penny,** 360
Mohiuddin, Syed M. (coauthor) see **Hilleman, Daniel E.,** 669
Mojaverian, Parviz (author) Cyclosporin Monitoring in Kidney Transplant Patients: Comparison Between Radioimmunoassay and High Performance Liquid Chromatography Methods (ab) 454; (coauthor) see **Larijani, Ghassem E.,** 454
Molindone, hepatotoxicity (CR) 744
Monooctanoin, adverse effects (FF) 711; biliary stones (CTF) 227; evaluation (FF) 708; pharmacokinetics (FF) 709
Montero, A. (coauthor) see **Jimenez-Alonso, J.,** 477
Moore, P. (coauthor) see **Hill, Malcolm,** 464
Moore, R.A. (coauthor) see **Beach, C.L.,** 451
Moore, Rodney T. (coauthor) see **Parish, Roy C.,** 199
Moore, Terri L. (coauthor) see **Abate, Marie A.,** 708
Morkunas, Anthony R. (coauthor) see **Gonzalez, Edgar R.,** 807
Morphine, cancer pain (CTF) 152; overdose (ab) 461; postoperative analgesia (CTF) 952; tonic seizure (CTF) 686
Morris, L. (coauthor) see **Reedy, Michael E.,** 457
Morse, Gene D. (author) Individualization of Tobramycin Dosing during Continuous Ambulatory Peritoneal Dialysis (ab) 469
Moxalactam, bactericidal activity (CTF) 952; cerebrospinal fluid penetration (ab) 455; compared with cefamandole (RPR) 677; compared with cefazolin (RPR) 677; prolonged prothrombin time (CTF) 491; pulmonary hemorrhage (CTF) 228
Mozes, M.F. (coauthor) see **Maddux, Michael S.,** 452
Mulry, James T. (author) Guanabenz Therapy for Opiate Withdrawal (CR) 32
Munoz-Avila, J. (coauthor) see **Jimenez-Alonso, J.,** 477
Munroe, Wendy P. (author) Systemic Side Effects Associated with the Ophthalmic Administration of Timolol (DIR) 85
Munzenberger, Paul J. (author) The Effect of a Rapid Theophylline Assay on the Clinical Management of Patients with Asthma (ab) 448
Murphy, John E. (author) Latrinization of the Pharm.D., B.S., P.D. Debate (L) 950
Mylanta, compared with cimetidine, gastric ulcer (CTF) 952
Myocardial infarction, beta-blockers (TC) 581

N

Nadolol, compared with diazepam (CTF) 228; compared with hydrochlorothiazide (A) 632; infiltrative dermatitis, alopecia (CTF) 603, migraine (CTF) 227
Naftolin, Frederic (coauthor) see **Osathanondh, Rapin,** 445
Nahata, Milap C. (author) Adverse Effects of Meperidine, Promethazine and Chlorpromazine Combination for Sedation/Anesthesia in Pediatric Patients (ab) 445; (author) Author's Reply: Combination Drugs in India (L) 319; (author) book review, 684; (author) Ceftriaxone: A Third-Generation Cephalosporin (FF) 900; (author) Handwashing Prevents Infection (E) 738; (author) Variation in Prophylactic Antibiotic use in Pediatric Orthopedic Surgery (RPR) 834
Nalidixic acid, thrombocytopenia (CTF) 325; toxicity (CTF) 491
Naloxone, intestinal pseudoobstruction (CTF) 952; opioid overdose (L) 56; septic shock (CTF) 602; tardive dyskinesia (CTF) 227
Naltrexone, heroin withdrawal (CTF) 152
Naproxen, compared with ergotamine, migraine (CTF) 952; neoplastic fever (CTF) 686; sodium, migraine (CTF) 866
Nearman, H.S. (coauthor) see **Cowan, Ronald I.,** 455
Neims, Allen (coauthor) see **Massanari, Marc,** 462; (coauthor) see **Massey, Kenneth L.,** 462
Nelson, Robert C. (author) Comment: Poisoning Prevention (L) 210
Neomycin, oral, colon surgery (ab) 446
Neostigmine, shoulder-hand syndrome (CTF) 324
Netilmicin, ceftazidime, bactericidal acitvity (RPR) 932; gram negative-infections (RPR) 309; nephrotoxicity (CTF) 406; ototoxicity, compared with tobramycin (ab) 455; pharmacokinetics, neonates (ab) 445
Netter, Frank, honorary Doctor of Science degree (NC) 616
New Drug Evaluations, Cyclosporine, 90
News and Comments, 79, 159, 239, 330, 412, 503, 615, 695, 791, 879, 962; see also **Association News, Education and Research News, FDA News, General News, USPHS—CDC News, Obituaries, VIP News**
Nicks, H. (coauthor) see **Lampasona, Victor,** 465
Nicotine, breast milk (CTF) 68
Niemi, Brian (coauthor) see **Kramer, Warren,** 398
Nifedipine, chewing capsules (CTF) 405; combined with propranolol, diltiazem, or verapamil (CTF) 685; compared with propranalol, verapamil (CTF) 602; compared with terbutaline (CR) 369; exercise-induced myalgia (CTF) 325; irritable colon syndrome (CTF) 866; myocardial infarction (CTF) 227; nephrotoxicity (CTF) 406; periorbital edema (CTF) 867; preterm labor (CR) 369; quinidine interaction (CR) 829; urticaria pigmentosa (CTF) 151
Nightingale, C.H. (coauthor) see **White, R.L.,** 460
Nitrates, glaucoma (DIAS) 361
Nitrendipine, blood pressure reduction (CTF) 602
Nitrofurantoin, adverse reactions (DIR) 540
Nitroglycerin, adsorption to iv administration set (RPR) 572; iv tubing adsorption (L) 946; myocardial infarction (CTF) 67; transdermal (CTF) 151; transdermal, ineffectiveness (CTF) 866
Nitroprusside, arteriolar dilation (CTF) 405; infusion rates (CTF) 775; respiratory distress syndrome (CTF) 491
Nitzan, Menachem (coauthor) see **Garty, Ben-Zion,** 740
Nix, David E. (author) Amphotericin B Bladder Irrigation (DIAS) 299; (author) Ciprofloxacin Pharmacokinetics in Patients with Bone and Soft Tissue Infections (ab) 462
Nolan, Paul E. (author) Single-Dose Pharamacokinetics of Amiodarone (ab) 463
Nomogram, Moore-Smith, aminoglycoside nephrotoxicity (ab) 451
Norton, Jane A. (coauthor) see **Bertch, Karen E.,** 561
Nortriptyline, plasma levels (CTF) 603
Noud, Mary (author) Atropine Sulfate by Inhalation (DIAS) 732
Nuno, E. (coauthor) see **Jimenez-Alonso, J.,** 477
Nutrition, parenteral, hepatic drug metabolism (ab) 464
Nye, L. (coauthor) see **Tartaglione, Teresa A.,** 459

O

O'Neal, Welton, appointments at Medical University of South Carolina (NC) 616
Obituaries (NC), Miller, Russell R., 962
Ohsawa, Tomoji (author) Hepatitis Associated with Allopurinol (CR) 431
Ohtsubo, Masatoshi (coauthor) see **Ohsawa, Tomoji,** 431
Oksas, Richard M. (author) Possible Reaction with NSAIDs and Tartrazine (L) 478
Olson, David L. (coauthor) see **Meyer, Leeroy E.,** 213
Oncology Therapuetics, Cisplatin Nephrotoxicity: A Summary of Preventative Interventions, 362; Combination Antiemetic Therapy in the Control of Chemotherapy-Induced Emesis, 21; Duxorubicin: Alteration of Dose Scheduling as a Means of Reducing Cardiotoxicity, 259
Opinions, see **An Opinion, Editorials**
Optivite, premenstrual syndrome (A) 717
Oren, A. (coauthor) see **Conner, Dale P.,** 453; (coauthor) see **Vlasses, Peter H.,** 454
Ornato, J.P. (coauthor) see **Gonzalez, Edgar R.,** 449
Osathanondh, Rapin (author) Efficacy of Fenoprofen in the Treatment of Primary Dysmenorrhea (ab) 445; (coauthor) see **Kaul, Alan F.,** 369
Osterhaus, Jane T. (author) A Survey of State Board of Pharmacy Members and Continuing Education Providers' Views on Continuing Education (RPR) 134
Oszko, Barbara J. (coauthor) see **Weber, Robert J.,** 13
Otero, Carlos (coauthor) see **Criado, Antonio,** 673
Oxazepam, central nervous system symptoms (RPR) 38; compared with diazepam (CTF) 406
Oxygen, bleomycin pneumonitis (CR) 921

P

Paladino, Joseph A. (coauthor) see **Haas, Curtis E.,** 843
Palsy, Bernard H. (coauthor) see **Bodendorfer, Thomas W.,** 827
Paloucek, F.P. (coauthor) see **Fischer, James H.,** 460
Parashos, Peter J. (author) Comment: Revised Treatment of Ulcerative Stomatitis (L) 139
Parenteral nutrition, see **Nutrition**
Parish, Roy C. (author) Seizures Following Oral Lidocaine for Esophageal Anesthesia (CR) 199
Park, Glen D. (author) Comparison of the Effects of an Activated Charcoal Regimen on Digoxin and Digitoxin Clearance (ab) 447; (author) The Effects of Activated Charcoal on Digoxin and Digitoxin Clearance (RPR) 937; (coauthor) see **Spector, Reynold,** 916
Parker, Paul F. (coauthor) see **Elenbaas, Robert M.,** 149
Patel, Jayant A. (author) book review, 601
Patients, outpatient intravenous therapy (S) 293
Paton, T.W. (coauthor) see **Walker, Scott E.,** 468
Patrias, John M. (coauthor) see **DiPiro, Joseph T.** 446; (coauthor) see **Longe, R. Leon,** 252
Pau, A.K. (coauthor) see **Maddux, Michael S.,** 452
Pearson, Robert E. (coauthor) see **Lyon, Ronald A.,** 390
Peeler, D. (coauthor) see **Hill, Malcolm,** 464
Pefloxacin, aminophylline interaction (L) 945
Pellegrin, Patrick (author) Gitoxin—A Challenger for Digoxin? (L) 945
Pellerin, Michel (coauthor) see **LeBel, Marc,** 932
Penicillamine, dermatosis (CTF) 776; teratogenesis (CTF) 68
Penicillin, rifampin, group A streptococcal pharyngitis (CTF) 686
Penn, Dennis H. (author) book review, 683
Pentamidine, sciatic nerve damage (L) 762
Pentazocine, compared with ceruletide (RPR) 433; patient-controlled analgesia (ab) 457; renal colic (RPR) 433
Pentobarbital, chemotherapy-induced emesis (OT) 23
Pentoxifylline, adverse reactions (FF) 345; evaluation (FF) 345; interference, theophylline assays (ab) 467; peripheral occlusive arterial disease (CTF) 67; pharmacokinetics (FF) 345
Pepine, C.J. (coauthor) see **Pieper, John A.,** 465
Perrier, Donald G. (coauthor) see **Elenbaas, Robert M.,** 149
Perry, Paul J. (author) Assessment of Addiction Liability of Benzodiazepines and Buspirone (TC) 657; (author) book review, 774
Personnel Placement see separate section: **ADVERTISERS**
Pertussis, routine immunization (TC) 729
Perucca, Emilio (coauthor) see **Bonati, Maurizio,** 913
Peterson, Charles D. (coauthor) see **Lake, Kathleen D.,** 459
Pevonka, M. Peter (author) book review, 773
pH see **Hydrogen ion concentration** (ab) 449
PharmaCE see also **Drug Intelligence and Clinical Pharmacy, PharmaCE;** test questions, 77, 157, 234, 329, 410, 501, 605, 687, 786, 877, 960
Pharmacodynamics, triazolam (ab) 449
Pharmacokinetics, acyclovir (ab) 466; acyclovir, peritoneal dialysis (ab) 453; alprazolam (ab) 450; aminoglycosides (ab) 466; aminoglycosides, pediatrics (ab) 462; amiodarone (ab) 463; antipyrine (ab) 446; aspirin (ab) 461; azlocillin (ab) 450, 459; bucindolol (ab) 453; carbamazepine (RPR) 941; carbamazepine, cimetidine (ab) 456; cefamandole (ab) 460; cefotaxime (ab) 450; cefotaxime, obesity (ab) 463; ceftizoxime (ab) 450; cefuroxime (ab) 460; cimetidine (CR) 203; cimetidine, carbamazepine (ab) 456; ciprofloxacin (ab) 462; clindamycin (ab) 450; cyclosporine (A) 102, (ab) 450, 451, (NDE) 91; digoxin monitoring (RPR) 45; dopamine, tobramycin (ab) 448; fludarabine phosphate (ab) 457; furosemide (ab) 448; gentamicin (ab) 469; glyburide, cimetidine, ranitidine (ab) 461; imipenem (ab) 467; lidocaine, preeclampsia (ab) 456; methotrexate, cisplatin (ab) 467; model-independent program (RPR) 125; netilmicin, neonates (ab) 445; phenytoin ibuprofen (ab) 447; phenytoin, peritoneal dialysis (ab) 465; piperacillin, (ab) 459, aminoglycosides (ab) 455, hemodialysis (ab) 455; quality assurance (ab) 462; slow-release cathartics (ab) 462; suflamethoxazole (ab) 453; theophylline (ab) 448, 449; theophylline, amiodarone (ab) 454, tetracycline (ab) 463, neonates (ab) 445, sustained-release (ab) 468; tobramycin microcomputer program (ab) 451, tobramycin peritoneal dialysis (ab) 469; tolazamide (ab) 458; tolbutamide, cimetidine (ab) 465, ranitidine (ab) 465; trauma (CC) 799; triazolam (ab) 449; valproic acid, enteric-coated (ab) 460
Pharmacy, clinical, cardiology units (ab) 460, cost-benefit (ab) 448, (RPR) 575, prescribing impact (RPR) 440, specialty practice (O) 149; European practice (D) 320; fellowships (A) 57, 219; home antibiotic programs (S), 285, 288; home health care (S) 282; residency training (E) 60; state board, continuing education (RPR) 134; survival strategy (E) 655
Phelps, Stephanie J., (author) Evaluation of a Digoxin-Like Immunoreactive Substance in Pediatric Patients (ab) 466
Phenelzine, abrupt substitution (CR) 825; acute organic psychosis (CTF) 603; bulimia (CTF) 325; pyridoxine deficiency (CTF) 228; sulfate, catecholamines (ab) 455
Phenobarbital, asphyxiated neonates (CTF) 867; compared with mannitol (CTF) 405; concentrations, prediction (ab) 469; epilepsy (CTF) 953
Phenol, metrizamide, glycerin, refractory spasticity (CTF) 952
Phenolphthalein, pancreatitis (CTF) 152
Phenylpropanolamine, interacerebral hemorrhage (CTF) 686; overdose (CTF) 152
Phenytoin, Bayesian forecasters vs. nomograms (ab) 469; compared with sodium valproate (CTF) 775; concentrations, prediction (ab) 469, renal dysfunction (ab) 465; disposition, peritoneal dialysis (ab) 465; erythema multiforme (CR) 114; in vitro adsorption (L) 584; interactions, theophylline (CR) 34; laboratory parameters (RPR) 561; once-daily dosing (L) 584; peritoneal dialysis (CR) 429; pharmacokinetics, ibuprofen (ab) 447
Phillips, J. (coauthor) see **Schwartz, R.,** 457
Phillips, J. Paul (coauthor) see **Smith, Randall B.,** 449
Physical Assessment, Peripheral Vascular and Lymphatic Systems, 252
Physostigmine, Alzheimer's disease (CTF) 490
Piecoro, John J., Jr. (coauthor) see **Rapp, Robert P.,** 56
Pieper, John A. (author) Free and Total Diltiazem Concentrations: Predictors of Cardiovascular Responses (ab) 465; (coauthor) see **Hill, Malcolm,** 464; (coauthor) see **Webster, W.B.,** 463
Pierson, W.P. (coauthor) see **Lehmann, Craig R.,** 460
Pietruszka, Laura J. (author) Evaluation of Cisplatin-Lithium Interaction (CR) 31
Pihl, Robert O. (coauthor) see **Marinier, Raymonde L.,** 40
Pimozide, adverse reactions (FF) 423; evaluation (FF) 421; pharmacokinetics (FF) 422
Pindolol, compared with hydrochlorothiazide (A) 632
Piperacillin, concomitant aminoglycosides (ab) 455; neutropenia (CR) 112; pharmacokinetics (ab) 459, (CR) 427, hemodialysis (ab) 455
Piroxicam, acute interstitial nephritis (CTF) 686; overdose (CTF) 68; warfarin interaction (CR) 556
Pisenti, Lisa (coauthor) see **Hart, Linda L.,** 297
Pitlik, Silvio D. (coauthor) see **Lustig, Shamir,** 763
Plachetka, J.R. (coauthor) see **Cubberley, R.B.,** 456
Pleasants, Roy A. (coauthor) see **DeVito, Joseph M.,** 837
Pleiss, Michael A. (author) book review, 322
Plumridge, Richard J. (author) Comment: Drug Bulletins and Prescribing (L) 318
Pneumococcal vaccine, acute otitis media (DIAS) 735; alcoholic liver disease (CTF) 227
Pneumonia, nosocomial, dosage adjustments (ab) 462
Pohorylo, E. (coauthor) see **Massanari, Marc,** 462
Poland, Joseph M. (coauthor) see **Parashos, Peter J.,** 139
Polk, Ronald E. (coauthor) see **Tartaglione, Teresa A.,** 188, 459
Ponte, Charles D. (author) book review, 601; (author) Suspected Procainamide-Induced Angioedema (L) 139; (author) Tolmetin-Induced Urticaria/Angioedema (L) 479
Porter, R. Stephen (author) book review, 488
Potassium, supplementation (A) 176
Potassium citrate, adverse reactions (DSP) 536; evaluation (DSP) 536
Potassium clavulanate, amoxicillin, adverse reactions (FF) 418; amoxicillin, evaluation (FF) 415; amoxicillin, phar-

macokinetics (FF) 416
Povidone-iodine, vaginitis (CTF) 151
Powell, Dwight A. (coauthor) see **Kuhn, Robert J.,** 445; (coauthor) see **Nahata, Milap C.,** 834
Powell, J. Robert (coauthor) see **Cate, E.W.,** 465; (coauthor) see **Dalton, Michael J.,** 456, 941
Powell, Stephen H. (author) Positions Held by Graduates of Postgraduate Pharmacy Fellowship Programs (A) 57; (coauthor) see **Kaul, Alan F.,** 219
Poynor, W. (coauthor) see **Tartaglione, Teresa A.,** 459
Prasad, V. (coauthor) see **Jackson, M.,** 841
Prazepam, ranitidine, duodenal ulcer healing (CTF) 775
Praziquantel, parenchymal cysticercosis (CTF) 775
Prazosin, anaphylaxis (CTF) 686; compared with hydrochlorothiazide (A) 632
Prednisolone, compared with triamcinolone acetonide (CTF) 68
Prednisone, diphenhydramine, ephedrine, high-risk radiology (CTF) 490
Premenstrual syndrome, progesterone (DIAS) 297; review (A) 714
Primack, William A. (coauthor) see **Hays, Dennis P.,** 429
Probenecid, theophylline kinetics (L) 840
Procainamide, neutropenia (CTF) 867
Prochlorperazine, chemotherapy-induced emesis (OT) 23
Progesterone, premenstrual syndrome (A) 719, (CTF) 406, (DIAS) 297
Progestins, teratogenesis (CTF) 775
Promethazine, meperidine, chlorpromazine, pediatrics, respiratory depression (ab) 445
Propranolol, combined with diltiazem, verapamil, or nifedipine (CTF) 685; compared with acebutolol (CTF) 490; compared with hydrochlorothiazide (A) 632; compared with lorazepam, neuroleptic-induced akathisia (CTF) 953; compared with nifedipine (CTF) 602; controlled hypotension (CTF) 151; diltiazem, paroxysmal supraventricular tachycardia (CTF) 490; essential hypertension (CTF) 151; glaucoma (CTF) 406; intraoperative (CTF) 227; mania (CTF) 491; membrane stabilization (L) 583; migraine (CTF) 67; protein binding (ab) 463; ventricular arrhythmias (CTF) 685; verapamil, angina (CTF) 602
Propylthiouracil, hepatitis (CR) 740
Prostaglandin E$_1$, see **Alprostadil**
Proulx, Susan (author) Beta-Blocker-Induced Retroperitoneal Fibrosis (DIAS) 359
Pseudomembranous colitis, treatment (DIAS) 28
Psychotropic drugs, mentally ill females (L) 844; women (RPR) 40
Ptachcinski, Richard J. (author) Cyclosporine (NDE) 90; (author) Dose-Dependent Absorption of Cyclosporine (ab) 450; (coauthor) see **Burckart, Gilbert J.,** 450; (coauthor) see **Howrie, Denise L.,** 425; (coauthor) see **Venkataramanan, Raman,** 451
Purich, E.D. (coauthor) see **Straughn, Arthur B.,** 461
Pyridostigmine, shoulder-hand syndrome (CTF) 324
Pyridoxine, premenstrual syndrome (A) 718, (CTF) 867
Pyszczynski, D.R. (coauthor) see **Lander, Roger D.,** 450

Q

Quality assurance, pharmacokinetic dosing services (ab) 465
Quality control, antiepileptic drug monitoring (TM) 913
Quee, Connie K. (coauthor) see **Park, Glen D.,** 937
Quinidine, effect of anticonvulsants (ab) 461; Emit vs. HPLC assays (ab) 460; nifedipine interaction (CR) 829; sustained-release, brand comparison (ab) 460; sustained-release, trough concentrations (ab) 459
Quinine, blindness (CTF) 603
Quintiliani, R. (coauthor) see **White, R.L.,** 460

R

Raebel, Marsha A. (author) Effect of Phenelzine Sulfate on Plasma Catecholamines (ab) 455
Rainey, J. (coauthor) see **Berchou, Richard C.,** 449
Ramanathan, Jaya (coauthor) see **Bottorff, Michael B.,** 456
Ramphal, Reuben (coauthor) see **Yost, Richard L.,** 509
Rand, Kenneth H. (coauthor) see **Gotz, Vincent P.,** 436
Ranitidine, arthritis (CR) 201; bradycardia, drowsiness (CTF) 776; carbamazepine pharmacokinetics (RPR) 941; compared with antacids (DSP) 807; compared with cimetidine (CTF) 490; duodenal ulcer (CTF) 67, 490; effect on glyburide pharmacokinetics (ab) 461; metoclopramide, compared with magnesium trisilicate (CTF) 775; prazepam, duodenal ulcer healing (CTF) 775; stress ulcer prophylaxis (DSP) 807; tolbutamide elimination (ab) 465; ulcer recurrence (CTF) 151; urticaria (DIAS) 662
Rapp, Robert P. (author) Authors' Reply: Extended Half-Life, Second-Generation Cephalosporins in Surgical Prophylaxis (L) 843; (author) Authors' Reply: Guidelines for IV Drugs (L) 56; (author) Hospital Intravenous Drug Administration in the Era of Prospective Payment (E) 146; (author) The Role of the Extended Half-Life Second-Generation Cephalosporins in Surgical Prophylaxis (TC) 214; (coauthor) see **Bertch, Karen E.,** 561
Ravid, Mordchai (coauthor) see **Lishner, Michael,** 433
Ravis, William R. (coauthor) see **Beck, Diane E.,** 469
Reed, Michael D. (author) Evaluation of Antibiotics for Home Care Programs (S) 288
Reed, Ronald C. (author) Preliminary Findings for Intrasubject Variation in Theophylline Absorption Characteristics (ab) 448
Reeder, William (coauthor) see **Meyer, Leeroy E.,** 213
Reedy, Michael E. (author) Pentazocine for Patient-Controlled Analgesia (ab) 457
Repal, Randolph E. (author) Comment: Lidocaine Seizures (L) 680
Reitberg, Donald P. (author) A Rapid, Universal TI-59 Model Independent Pharmacokinetic Analysis Program Based on Statistical Moment Theory (RPR) 125
Remington, Helen St.C. (author) Methotrexate Blood Level Monitoring (CR) 372
Renal failure, nutritional support (A) 106
Research, regression to the mean (CT) 916
Research/Practice Reports, A Comparative Study of Gentamicin and Netilmicin in the Treatment of Gram-Negative Infections, 309; A Comparative Study of Laboratory Parameters in Head-Injured Patients Receiving Either Phenytoin or Placebo for 24 Months 561; A Rapid, Universal TI-59 Model-Independent Pharmacokinetic Analysis Program Based on Satistical Moment Theory, 125; A Survey of Prophylactic Antibiotic use for Total Joint Replacements in a Community Hospital, 753; A Survey of State Board of Pharmacy Members and Continuing Education Providers' Views on Continuing Education 134; Analgesic Effect of Ceruletide Compared with Pentazocine in Biliary and Renal Colic: A Prospective, Controlled, Double-Blind Study, 433; Antianxiety Drugs and Central Nervous System Symptoms in an Ambulatory Elderly Population, 37; Cost-Justification of a Clinical Pharmacist-Managed Anticoagulation Clinic, 575; Drug Information Roots: The Influence of Education and Training on the Philosophy and Activities of Hospital- and Drug Information Services, 390; Early use of Oral Theophylline in Hospitalized Chronic Obstructive Pulmonary Disease Patients: Cost-Containment Through Medical Education, 749; Effect of Filtering Amphotericin B Infusions on the Incidence and Severity of Phlebitis and Selected Adverse Reactions, 436; Estimation of Renal Creatinine Clearance in Patients with Unstable Serum Creatinine Concentrations: Comparison of Multiple Methods, 385; Estimation of the Steady-State Volume of Distribution for Digoxin: A Comparison of Model-Independent Methods with a Two-Compartment Model in Healthy Volunteers, 837; Evaluation of a Digoxin Pharmacokinetic Monitoring Service in a Community Hospital, 45; Evaluation of Appropriateness and Interpretation of Serum Theophylline Assays, 380; Evaluation of High-Dose Tobramycin-Carbenicillin Therapy in Pseudomonal Infections in Cystic Fibrosis, 757; Family Practice Residents' Prescribing Patterns, 205; Feasibility and Cost Savings of Intravenous Administration of Aminoglycosides in Outpatients with Cystic Fibrosis, 52; Impact of Clinical Pharmacy Services on Prescribing on a Cardiothoracic/Vascular Surgical Unit, 440; Long-Term Experience with Lofexidine in the Treatment of Mild-to-Moderate Essential Hypertension, 928; Measurement of Tobramycin Concentrations in Saliva, 378; Nitroglycerin Adsorption to a Combination Polyvinyl Chloride, Polyethylene Intravenous Administration Set, 572; Psychotropic Drug use by Women: Demographic, Lifestyle, and Personality Correlates, 40; Ranitidine does not Alter Single-Dose Carbamazepine Pharmacokinetics in Healthy Adults, 941; Serum Bactericidal Activity of Ceftazidime Increased by Netilmicin, 932; Subcutaneous Epinephrine vs. Nebulized Metaproterenol in Acute Asthma, 567; The Antiemetic Activity of Droperidol Administered by Intramuscular Injection During Cisplatin Chemotherapy: A Pilot Study, 118; The Effect of In-Line Filtration on Tobramycin Delivery, 122; The Effect of Single Doses of Cimetidine on Estimated Hepatic Blood Flow, 831; The Effects of Activated Charcoal on Digoxin and Digitoxin Clearance, 937; The Lack of Inactivation of Tobramycin by Cefazolin, Cefamandole, and Moxalactam In Vitro, 677; The use of Veterinary Clinics for the Education of Pharmacy Students, 315; Ticlopidine as a Hemorrhagic Risk Factor in Coronary Surgery, 673; Variation in Prophylactic Antibiotic use in Pediatric Orthopedic Surgery, 834
Rheumatoid arthritis, methotrexate (A) 349
Rho Chi Lecture Award, Is it Possible to Teach Scientific Creativity in the Pharmaceutical Sciences? Anecdotes and Memorabilia, 590; Personal Adventures in Biopharmaceutical Research During the 1953-1984 Years, 265
Rhodes, Pamela J. (coauthor) see **Rhodes, Richard S.,** 556
Rhodes, Richard S. (author) A Warfarin—Piroxicam Drug Interaction (CR) 556
Rich, S. (coauthor) see **Barbarash, Rick A.,** 466
Rickman, Lucy A. (coauthor) see **Carter, Charles A.,** 812
Ries, John C. (coauthor) see **Meyer, Leeroy E.,** 213
Rifampin, penicillin, group A streptococcal pharyngitis (CTF) 686; verapamil interaction (CR) 559
Riley, David A. (author) Professional Development Degrees (L) 585
Riley, L.J. (coauthor) see **Rocci, Mario L.,** 453; (coauthor) see **Vlasses, Peter H.,** 454
Rindone, Joseph P. (coauthor) see **Munroe, Wendy P.,** 85
Ringer, Joseph (author) Streptokinase IV Protocol in Acute MI Patients (L) 764
Rivera, G. (coauthor) see **Christensen, M.L.,** 467
Rivey, Michael P. (author) Aminoglycoside Monitoring in the Neonate (DIAS) 908
Roberts, Pamela (coauthor) see **Park, Glen D.,** 937
Robinson, C.A. (coauthor) see **Beck, Diane E.,** 469; (coauthor) see **Farringer, John A.,** 461
Robinson, J. Daniel (coauthor) see **Taylor, William J.,** 818
Robinson, William A. (coauthor) see **Elenbaas, Robert M.,** 567
Rocci, Mario L., Jr., (author) The Effect of Single Doses of Cimetidine on Estimated Hepatic Blood Flow (RPR) 831; (author) Steady-State Bucindolol Pharmacokinetics in Patients with Moderate to Severe Essential Hypertension (ab) 453; (coauthor) see **Cummings, Doyle M.,** 467; (coauthor) see **Larijani, Ghassem E.,** 454; (coauthor) see **Vlasses, Peter H.,** 454
Rodman, John H. (coauthor) see **Brundage, Diane M.,** 453; (coauthor) see **Elenbaas, Robert M.,** 149; (coauthor) see **Fletcher, Courtney V.,** 466; (coauthor) see **Teresi, Mary E.,** 466
Rodriguez, Jose Maria Rodriguez (coauthor) see **Barbero, Julita Rodriguez,** 394
Rogers, J.R. (coauthor) see **Cate, E.W.** 465
Romankiewicz, John A. (coauthor) see **Stanaszek, Walter F.,** 176
Rosenfeld, Joseph B. (coauthor) see **Lustig, Shamir,** 763
Rosenthal, Alan R. (author) Cost-Benefit Analysis of Clinical Pharmacy Services (ab) 448
Rosenthal, J. Thomas (coauthor) see **Howrie, Denise L.,** 425; (coauthor) see **Ptachcinski, Richard J.,** 450
Rosman, Allen W. (coauthor) see **Lyon, Ronald A.,** 390
Rotmensch, Heschi H. (coauthor) see **Vlasses, Peter H.,** 454, 581
Rotschafer, John C. (coauthor) see **Bailie, George R.,** 840; (coauthor) see **Lam, Y.W. Francis,** 451; (coauthor) see **Steinberg, Irving,** 464
Rubenfire, M. (coauthor) see **Bach, David S.,** 446
Ruffalo, Richard L. (coauthor) see **Garabedian-Ruffalo, Susan M.,** 304
Rumack, Barry H. (author) Acetaminophen: Acute Overdose Toxicity in Children (TC) 911
Rumsfield, J.A. (coauthor) see **West, Dennis P.,** 464
Ryan, Joseph L. (coauthor) see **Elenbaas, Robert M.,** 567
Rybak, Michael J. (coauthor) see **Bach, David S.,** 211
Ryerson, G.G. (coauthor) see **Gotz, Vincent P.,** 463
Rynearson, R.R. (coauthor) see **Raebel, Marsha A.,** (S) 455

S

Saccar, C.L. (coauthor) see **Larijani, Ghassem E.,** 454
Safarik, Jana (coauthor) see **Wells, Barbara G.,** 142
Safon, Leonard E. (coauthor) see **Kaul, Alan F.,** 369
Sagraves, Rosalie (author) Tolmetin in Breast Milk (L) 55
Salazar, R. (coauthor) see **Reed, Ronald C.,** 448
Salva, Kathryn M. (author) Inadvertent Overdose of Morphine (ab) 461
Sargenti, Christine (author) Evaluation of Appropriateness and Interpretation of Serum Theophylline Assays (RPR) 380
Savitzky, C.W. (coauthor) see **Rocci, Mario L.,** 453
Sawin, H. (coauthor) see **MacCosbe, Paul E.,** 446
Scalley, Robert D. (author) The use of Veterinary Clinics for the Education of Pharmacy Students (RPR) 315
Scarborough, John, director, American Institute of the History of Pharmacy (NC) 792
Scavone, Joseph M. (coauthor) see **Onathanondh, Rapin,** 445; (coauthor) see **Townsend, Raymond J.,** 447
Schaber, Daniel E. (author) Nitroglycerin Adsorption to a Combination Polyvinyl Chloride, Polyethylene Intravenous Administration Set (RPR) 572
Schell, Ronald F. (coauthor) see **Lefrock, Jack L.,** 309
Schentag, Jerome J. (author) Dual Individualization in Gram-Negative Pneumonia. Shortening the Duration of Treatment of Nosocomial Pneumonia by Precision Dosage Adjustments (ab) 462; (coauthor) see **De Vito, Joseph M.,** 837; (coauthor) see **Nix, David E.,** 462; (coauthor) see **Reitberg, Donald P.,** 125; (coauthor) see **Swanson, Douglas J.,** 467
Schlesinger, P. (coauthor) see **Lau, Alan,** 457
Schneider, Philip J. (author) How can Pharmacists Develop and Implement a Home Antibiotic Program (S) 285
Schneiweiss, Fred (coauthor) see **Proulx, Susan,** 359
Schrager, B.R. (coauthor) see **Gilman, Miles E.,** 446
Schwartz, H.J. (coauthor) see **Reed, Ronald C.,** 448
Schwartz, R. (author) Pharmacokinetic Study of Intraperitoneal Fludarabine Phosphate (ab) 457
Schweizer, Robert (coauthor) see **Chow, Moses Sing Sum,** 385
Seatone (green-lipped muscle extract), rheumatoid arthritis (CTF) 686
Secobarbital chemotherapy-induced emesis (OT) 23
Seizures, lidocaine (CR) 199
Self, Timothy H. (author) Early use of Oral Theophylline in Hospitalized Chronic Obstructive Pulmonary Disease Patients: Cost-Containment Through Medical Education (RPR) 749
Selman, W.R. (coauthor) see **Cowan, Ronald I.,** 455
Semla, T.P. (author) Misperceptions by the Elderly of Prescription Drug Purposes (ab) 452
Shah, D.S. (author) Comment: Combination Drugs in India (L) 319
Shaughnessy, Allen F. (author) Comment: Exercise and Beta-Blockers (L) 586; (author) Potential uses for Metoclopramide (A) 723
Shaughnessy, T. (coauthor) see **Vaughan, Leigh,** 452
Shaw, B. (coauthor) see **Burckart, Gilbert J.,** 450
Shikuma, Lois R. (coauthor) see **Lam, Y.W. Francis,** 451
Shimp, Leslie A. (author) Potential Medication-Related Problems in Noninstitutionalized Elderly (G) 766
Shuper, Avinoam (author) Carbamazepine-Induced Hair Loss (CR) 924
Sibai, Baha M. (coauthor) see **Bottorff, Michael B.,** 456
Sica, D.A. (coauthor) see **Comstock, Thomas J.,** 465
Simethicone, infantile colic (CTF) 953
Singsank, Mark J. (coauthor) see **Elenbaas, Robert M.,** 567
Sinkule, Joseph A. (coauthor) see **Abdelfathah, E.,** 456
Sintek, Charles D. (coauthor) see **Rhodes, Richard S.,** 556
Sirgo, Mark A. (coauthor) see **Cubberley, R.B.,** 456
Sklar, Stephen J. (author) Enhanced Theophylline Clearance Secondary to Phenytoin Therapy (CR) 34
Skoutakis, Vasilios A. (coauthor) see **Carter, Charles A.,** 812; (coauthor) see **Gollamudi, R.,** 226
Slaughter, Richard L. (author) Blood Sampling Errors: A Problem for Therapeutic Drug Monitoring Services (TM) 368; (author) Hepatic Drug Clearance Following Traumatic Injury (CC) 799; (coauthor) see **Farringer, John A.,** 461; (coauthor) see **Taylor, William J.,** 818

Smego, Raymond A. (author) Home Intravenous Antibiotic Therapy: Logistics of Delivery within Different Health-Care Settings (ab) 461
Smith, Bruce R. (author) Amoxicillin-Potassium Clavulanate: A Novel Beta-Lactamase Inhibitor (FF) 415
Smith, Gary H. (author) Flecainide: A New Class Ic Antidysrhythmic (FF) 703
Smith, Ian L. (coauthor) see **Reitberg, Donald P.**, 125; (coauthor) see **Swanson, Douglas J.**, 467
Smith, Randall B. (author) Effect of Dosing Regimen on Alprazolam Psychomotor Effects and Kinetics (ab) 450; (author) Temporal Variation in Triazolam Pharmacokinetics and Pharmacodynamics after Oral Administration (ab) 449; (coauthor) see **Kubacka, Renee T.**, 450
Smith, Robert E. (coauthor) see **Frost, R. Wayne**, 481
Smith, Robert V. (coauthor) see **Talbert, Robert L.**, 448
Smith, Seth C. (author) Authors' Reply: Monitoring Pediatric IV Drugs (L) 210
Smith, Thomas W., Therapeutic Frontiers Lecture Award (ACCP) 778
Smolinske, Susan C. (editor) Current Therapeutic Findings, 67, 151, 227, 324, 405, 490, 602, 685, 775, 866, 954
Snidero, Mario (author) Is Ambulatory Therapeutic Digoxin Monitoring Useful? (TM) 660
Snow, D. (coauthor) see **Reedy, Michael E.**, 457
Sodium citrate, cesarean section (CTF) 67
Sodium fluoride, calcium gluconate, vitamin D, otospongiosis (CTF) 775
Sokoloff, B.J. (coauthor) see **Osathanondh, Rapin**, 445
Soman, Michael (author) A Possible Case of Carbamazepine-Induced Pancreatitis (CR) 925; Somotostatin, compared with vasopressin (CTF) 602; variceal hemorrhage (CTF) 602
Soyka, L. (coauthor) see **Rocci, Mario L.**, 453
Spain, pharmacy education (L) 319
Spector, Reynold (author) Regression to the Mean: A potential Source of Error In Clinical Pharmacological Studies (CT) 916; (coauthor) see **Park, Glen D.**, 447, 937
Spermicides, vaginal, birth defects (CTF) 685
Spiekerman, A.M. (coauthor) see **Raebel, Marsha A.**, 455
Spierer, Diane N. (author) Caffeine Citrate: An Alternative to Theophylline for Apnea in Prematurity (L) 762
Spirometer, hand-held theophylline monitoring (ab) 447
Spironolactone, acne (CTF) 151
Spivack, George (coauthor) see **Goldberg, Emanuel**, 468
Spoerke, David G. (coeditor) see **Smolinske, Susan D.**, 602, 685
Spunt, Avery (coauthor) see **Fischer, James H.**, 460
Srebro, J. (coauthor) see **Barbarash, Rick A.**, 466
Stachowski, J. Scott (coauthor) see **Kaul, Alan F.**, 219
Stahl, Bracha (coauthor) see **Shuper, Avinoam**, 924
Stanaszek, Walter F. (author) Current Approaches to Management of Potassium Deficiency (A) 176
Starzl, Thomas E. (coauthor) see **Burckart, Gilbert J.**, 450; (coauthor) see **Venkataramanan, Raman**, 451
Status asthmaticus, halothane (CR) 307
Staubus, Alfred E. (coauthor) see **Mirtallo, Jay M.**, 464
Stein, Z.L.G. (author) Comment: Hypophosphatemia (L) 398; (coauthor) see **Barkin, Robert L.**, 211
Steinberg, Irving (author) Assay-Dependent Differences in Pharmacokinetic Dosage Regimen Determination: Analysis of Established Aminoglycoside Assays (ab) 464
Stellato, T.A. (coauthor) see **Danziger, Larry H.**, 455
Steroids, cortico- croup (DIAS) 360; intensive care unit syndrome (CC) 16
Stewart, Clinton F. (author) Cyclosporine Disposition in Patients with Liver Disease (ab) 451; (coauthor) see **Pheips, Stephanie J.**, 466
Stewart, Ronald B. (coauthor) see **Hale, William E.**, 37; Outstanding University of Florida Faculty award (NC) 504
Stimmel, Glen L. (author) book review, 153
Straughn, Arthur B. (author) Steady-State Aspirin and Metabolite Pharmacokinetics after Administration of Immediate and Controlled-Release Dosage Forms (ab) 461; (coauthor) see **Lalonde, Richard L.**, 449
Streptokinase, acute myocardial infarction (L) 764; bleeding (CTF) 152
Streptomycin, vertigo (CTF) 67
Sucralfate, acute GI bleeding (CTF) 405; compared with cimetidine (CTF) 490; interaction, aspirin (ab) 457; mouth ulcers (L) 480; plasma warfarin concentration (ab) 456; reflux esophagitis (CTF) 685; upper GI hemorrhage (CTF) 490
Sufentanil, cardiovascular stability (CTF) 866
Sulfacetamide, erythema multiforme (CTF) 776
Sulfamethoxazole, pharmacokinetics, AIDS (ab) 453
Sulfasalazine, infertility (CTF) 228
Sulfinalol, effects during exercise (ab) 451
Sulfisoxazole, otitis media prophylaxis (CTF) 867
Sulindac, lithium therapy (CR) 374; parkinsonism (CTF) 491
Sutherland, Earl W., III (coauthor) see **Golightly, Larry K.**, 302
Svec, Jennifer M. (coauthor) see **Lum, Bert L.**, 259
Sveska, Kim J. (author) Nitrates may not be Contraindicated in Patients with Glaucoma (DIAS) 361
Swanson, Douglas J. (author) Degradation Kinetics of Imipenem in NaCl 0.9% and in Serum (ab) 467; (coauthor) see **Schentag, Jerome J.**, 462
Swenson, Claudia (coauthor) see **Soman, Michael**, 925
Swift, Brian (coauthor) see **Bond, William S.**, 742
Swintosky, Joseph V. (author) Personal Adventures in Biopharmaceutical Research During the 1953-1984 Years (A) 265
Szefler, S. (coauthor) see **Vaughan, Leigh**, 452

T

Taber, David R. (author) Author's Reply: Aminoglycoside Dosing (L) 396
Talbert, Robert L. (author) Effect of Sucralfate on Plasma Warfarin Concentration in Patients Requiring Chronic Warfarin Therapy (ab) 456; (author) Furosemide Kinetics in Young and Elderly Subjects (ab) 448
Talliman, R.D. (coauthor) see **Dasta, Joseph F.**, 448
Tamoxifen, endometrial cancer (CTF) 603
Tan, Lelian (coauthor) see **Hart, Linda L.**, 297
Tankanow, Roberta M. (coauthor) see **Colvin, Carol L.**, 421
Tannenbaum, Renee P. (author) Comment: Indomethacin Sustained-Release (L) 681
Tanner, David J. (author) Health Care Cost-Containment in a Changing Health Care World (S) 291
Tao, Glen K. (author) Amoxapine-Induced Tardive Dyskinesia (CR) 548
Tartaglione, Teresa A. (author) Author's Reply: Ceforanide Half-Life (L) 588; (author) Comparative Pharmacokinetics of Azlocillin and Piperacillin Following Multiple Doses in Healthy Volunteers (ab) 459; (author) Review of the New Second-Generation Cephalosporins: Cefonicid, Ceforanide, and Cefuroxime (DSP) 188
Taylor, Bruce D. (coauthor) see **Lloyd, Charles W.**, 203, 588
Taylor, Jerry (coauthor) see **Alexander, Michael R.**, 403
Taylor, R.J. (coauthor) see **Ptachcinski, Richard J.**, 450
Taylor, William J. (author) Therapeutic Monitoring: Establishing a Pharmacy-Based Therapeutic Drug Monitoring Service, 818; (coauthor) see **McLeod, Donald C.**, 473; (editor) Therapeutic Monitoring, 660, 913
Teague, S. (coauthor) see **Hamilton, Stephen F.**, 451
Terazosin, once daily dosing (ab) 454
Terbutaline, compared with nifedipine (CR) 369; pancreatic fistula output (CTF) 602; preterm labor (CR) 369
Teresi, Mary E. (author) Comparison of Bayesian and Weighted Least Squares Methods for Optimizing Aminoglycoside Therapy in Pediatric Patients (ab) 466; (coauthor) see **Crom, William R.**, 467
Terfenadine, adverse reactions (FF) 816; evaluation (FF) 812; pharmacokinetics (FF) 814
Testosterone propionicum, episodic cluster headache (CTF) 602
Tetracycline, compared with erythromycin, resistance (CTF) 952; effect on theophylline (ab) 463; hydrocele (CTF) 406
Tetrahydrocannabinol, chemotherapy-induced emesis (OT) 23
Thadani, U. (coauthor) see **Hamilton, Stephen F.**, 451
Thalidomide, rheumatoid arthritis (CTF) 228
Tham, S.Y. (coauthor) see **Straughn, Arthur B.**, 461
Theophylline, absorption characteristics (ab) 448; assays, pentoxifylline interference (ab) 467; capillary blood test (ab) 452; compared with caffeine citrate (L) 762; compared with cromolyn (CTF) 152; cost-containment (RPR) 749; dosing, chronic asthma (ab) 458; effect of tetracycline (ab) 463; erythromycin interaction (CTF) 152; hand-held spirometer (ab) 447; high pressure liquid chromatography vs. fluorescent polarization immunoassay (ab) 449; interactions, pharmacokinetics (CR) 34, phenytoin (CR) 34, vidarabine (CTF) 68; pharmacokinetics, amiodarone (ab) 454; neonates (ab) 445; probenecid ineffectiveness (L) 840; rapid assay (ab) 448; serum assays (RPR) 380; sustained-release, effect of smoking, food (ab) 468
Therapeutic Controversies, Acetaminophen: Acute Overdose Toxicity in Children, 911; Assessment of Addiction Liability of Benzodiazepines and Busipirone, 657; Beta-Lactamase Inhibitors, 475; Exercise and Beta-Blocking Agents, 302; Routine Pertussis Immunization, 729; The Role of Beta-Blocking Agents Following Myocardial Infarction, 581; The Role of the Extended Half-Life Second-Generation Cephalosporins in Surgical Prophylaxis, 214
Therapeutic Monitoring, Blood Sampling Errors: A Problem and Challenge for Therapeutic Drug Monitoring Services, 368; Establishing a Pharmacy-Based Therapeutic Drug Monitoring Service, 818; Is Ambulatory Therapeutic Digoxin Monitoring Useful?, 660; Quality Control in Antiepileptic Drug Monitoring in Italy, 913; Therapeutic Drug Monitoring as a Standard of Care,473
Thiethylperazine, dystonia (CR) 550
Thioridazine, bioequivalence (O) 847
Thiosulfate sodium, cisplatin, nephrotoxicity (CTF) 603
Thomas, S. (coauthor) see **Cubberley, R.B.**, 456
Thompson, Michael (author) Use of Essential Amino Acid/Dextrose Solutions in the Nutritional Management of Patients with Acute Renal Failure (A) 106
Thyroid, labeling error (L) 945
Thyroxine, fetal growth acceleration (CTF) 491
Tibbs, Phillip A. (coauthor) see **Bertch, Karen E.**, 561
Ticarcillin, nephrotoxic aminoglycoside levels (CTF) 405
Ticlopidine, hemorrhagic risk factor (RPR) 673
Tillotson, James R. (coauthor) see **Lefrock, Jack L.**, 309
Tillson, S. (coauthor) see **Vaughan, Leigh**, 452
Timolol, compared with hydrochlorothiazide (A) 632; maleate, myasthenia gravis deterioration (CTF) 603; ophthalmic administration (DIR) 85
Tishler, M. (author) Cimetidine-Induced Eosinophilia (CR) 377
Tobramycin, cancer patients (CTF) 151; carbenicillin, cystic fibrosis (RPR) 757; filtration (RPR) 122; Hickman catheters (L) 477; inactivation by cephalosporins (RPR) 677; ototoxicity, compared with netilmicin (ab) 455; peritoneal dialysis (ab) 469; pharmacokinetics, dopamine (ab) 448, microcomputer program (ab) 451; saliva concentrations (RPR) 378
Tocainide, adverse reactions (FF) 515; evaluation (FF) 514; pharmacokinetics (FF) 515; rash, elevated serum transaminase, liver necrosis (CTF) 406
Tognoni, Gianni (coauthor) see **Bonati, Maurizio**, 913
Tolazamide, pharmacokinetics, age (ab) 458
Tolbutamide, elimination, effect of cimetidine, ranitidine (ab) 465
Tolmetin, breast milk (L) 55; urticaria, angioedema (L) 479
Tom, Michael (author) Combined use of Cromolyn and Inhaled Steroid in Asthma (DIAS) 185
Torti, Frank M. (coauthor) see **Lum, Bert L.**, 259
Total parenteral nutrition see **Nutrition**
Tourette's syndrome, pimozide (FF) 421
Townsend, Raymond J. (author) The Effects of Ibuprofen on Phenytoin Pharmacokinetics (ab) 447; (coauthor) see **DiPiro, Joseph T.**, 446; (coauthor) see **Kubacka, Renee T.**, 450
Traina, Gian Luigi (coauthor) see **Snidero, Mario**, 660
Translators see **Foreign Abstractors**
Transplantation, ceftizoxime, cefotaxime pharmacokinetics (ab) 450; marrow, cyclosporine (ab) 445; renal, cotrimoxazole (ab) 452; renal, cyclosporine monitoring (ab) 454
Tranylcypromine, abrupt substitution (CR) 825; Alzheimer's disease (CTF) 867
Trauma, hepatic drug clearance (CC) 799
Trazodone, atrial fibrillation (CTF) 867; cocaine interaction (CTF) 68; complete heart block (CTF) 491; divided vs. single dose (CTF) 228; ejaculatory inhibition (CTF) 228; hepatotoxicity (CTF) 953; mania (CTF) 152; peripheral edema (CTF) 867; tonic-clonic seizures (CTF) 776
Tress, J. (coauthor) see **White, R.L.**, 460
Triamcinolone acetonide, compared with prednisolone (CTF) 68
Triamterene/hydrochlorothiazide, product equivalence (CTF) 863
Triazolam, CNS toxicity (CR) 666; overdose (CTF) 867; pharmacokinetics, pharmacodynamics (ab) 449; prolonged sedation (L) 679
Triethylperazine, chemotherapy-induced emesis (OT) 23
Triglycerides, medium chain, seizures (CTF) 602
Trilostane, advanced metastatic breast cancer (CTF) 866; primary aldosteronism (CTF) 775
Trimethoprim, compared with co-trimoxazole (CTF) 490; dysuria-frequency syndrome (CTF) 490; pneumonia (CTF) 490
Trimethoprim/sulfamethoxazole, compared with cefaclor (CTF) 152; CSF shunt replacements (CTF) 775; recurrent urinary tract infections (CTF) 685
Troleandomycin, methylprednisolone, asthma (CTF) 686
True, Bev Lorraine (author) Review of the Etiology and Treatment of Premenstrual Syndrome (A) 714; (author) Routine Pertussis Immunization (TC) 729; (author) Switching Monoamine Oxidase Inhibitors (CR) 825
L-tryptophan, acute mania (CTF) 776
Tschida, V. (coauthor) see **MacCosbe, Paul E.**, 446
Turchet, Enzo N. (coauthor) see **Einarson, Thomas R.**, 201
Turlapaty, P. (coauthor) see **MacCosbe, Paul E.**, 446

U

Uden, Donald L. (coauthor) see **Schaber, Daniel E.**, 572
Ulcers, stress, histamine$_2$-receptor blockade (DSP) 807
Ultrafiltration, aminoglycosides (ab) 459
Umstead, Greg S. (author) Tobramycin Levels from Hickman Catheters (L) 477
Unger, Stefan H. (coauthor) see **Pleiss, Michael A.**, 322
United States Pharmacopeial Convention, Arthur Hull Hayes, Jr. Elected USPC President; John T. Fay, Jr. Elected Chairman of the Board, Se-ctr 2; Committees Formed in Preparation for USPC Quinquennial Meeting, Ja-ctr 2; Controversial Resolutions Passed, Se-ctr 3; Family Physicians Announce Drug Information Program Based on *USP DI*, Ja-ctr 3; Harry Shirkey Named Honorary Member of USPC, Se-ctr 2; Michigan Begins Patient Education Program, My-ctr 4; Nation's Oldest Organization of Health Professionals Meets in Washington, Se-ctr 1; Nominees for Election to USPC Board of Trustees Announced, My-ctr 1; Nominees for 1985-90 USP Committee of Revision Announced, My-ctr 2; Patient Counseling Research Project Under Way in Colorado, Ja-ctr 1; The Tradition Continues . . . USPC Quinquennial Meeting Program Defined, My-ctr 1; USAN and the USP Dictionary of *Drug Names*—It's Officially Official for Official Names, Ja-ctr 1; USP Burns the NF and Laboratory Mortgages, My-ctr 2; USP-Sponsored National Patient Counseling Competition Held at 1985 Student APhA Annual Meeting, My-ctr 3; USP/FDA to Continue Problem Reporting Programs, Ja-ctr 4; USPC Awards Three Honor Citations During Quinquennial Meeting Ceremony, Se-ctr 3; USPC Elects New Committee of Revision Se-ctr 3; 1985 USPC Quinquennial Meeting, Se-ctr 4; 71 New USP-NF Monographs Adopted, 11 New Dissolution Tests Added, Via First Supplement to *USP XXI-NF XVI*, Ja-ctr 3
Urokinase, pulmonary embolus (CTF) 324
Urosev, Ilija (coauthor) see **Ringer, Joseph**, 764
USPHS—CDC News (NC), Adverse Events Following Immunization, 330; Adverse Reactions to PYRS and Updated Recommendations for its use in the Prevention of Malaria, 332; Ansamcyin LM427, 330; Diphtheria-Tetanus-Pertussis Vaccine Shortage—United States, 79; Diphtheria, Tetanus, and Pertussis Guidelines, 791; Elimination of Rubella and Congenital Rubella Syndrome—U.S., 412; Human Rabies—Pennsylvania, 79; Influenza Prevention and Control, 695; Meningococcal Vaccines: Recommendation of Immunization Practices Advisory Committee, 615; Multiple Outbreaks of Kawasaki Syndrome—U.S., 239; Prospective Evaluation of Health Care Workers Exposed to Patients with AIDS, 330; Rabies Vaccine Recalled: Low Antibody Titers, 330; Reinstatement of Regular Diphtheria-Tetanus-Pertussis Vaccine Schedule, 503; Reye Syndrome—U.S., 1984, 239; Suicide and Suicide Attempts by the Nonmedical use of Drugs, 962; Tetracycline-Resistant Neisseria Gonorrhoeae, 879;

Update: Lyme Disease and Cases Occurring During Pregnancy, 879; Vaccine to Protect Children Against *Haemophilus Influenzae* Type B Disease, 503

V

Valenti, August J. (coauthor) see **Fraser, Gilles L.**, 757
Valproate, clonazepam, seizure improvement (CTF) 866; sodium, compared with phenytoin (CTF) 775, status epilepticus (CTF) 603, Sydenham's chorea (CTF) 490
Valproic acid, decreased selenium (CTF) 228; enteric coated, effect of meals (ab) 460; teratogenesis (CTF) 324
van der Kleijn, Eppo (coauthor) see **McLeod, Donald C.**, 859
Van der Lijn, Eva (coauthor) see **Djaldetti, Meir**, 583
Van Lith, Richard M. (author) Quinidine—Nifedipine Interaction (CR) 829
Van Reet, R.E. (coauthor) see **Lehmann, Craig R.**, 460
Van Thiel, D.H. (coauthor) see **Venkataramanan, Raman**, 451
Vance, J.W. (coauthor) see **Schentag, Jerome J.**, 462
Vancomycin, nephrotoxicity (DIAS) 907; renal dysfunction, individualized vs. nomogram dosing (ab) 465; standard vs. individualized dosing (ab) 459
Vari, A.J. (coauthor) see **Schentag, Jerome J.**, 462
Vasopressin, compared with somatostatin (CTF) 602
Vaughan, Leigh (author) Evaluation of a Capillary Blood Theophylline Test Requiring no Instrument (ab) 452; (coauthor) see **Milavetz, Gary**, 458
Venkataramanan, Raman (author) Cyclosporine Bioavailability in Liver Disease (ab) 451; (coauthor) see **Burckart, Gilbert J.**, 450; (coauthor) see **Howrie, Denise L.**, 425; (coauthor) see **Ptachcinski, Richard J.**, 90, 450
Verapamil, angina (CTF) 152; combined with propranolol, diltiazem, or nifedipine (CTF) 685; compared with clonidine, acute mania (CTF) 867; compared with lithium (CTF) 406; compared with nifedipine (CTF) 602; continuous, atrial tachycardia (ab) 466; effect on antipyrine (ab) 446; essential hypertension (CTF) 151; fetal supraventricular tachycardia (CTF) 324; inhaled, reactivity to methacholine (ab) 464; myocardial infarction (CTF) 67; propranolol, angina (CTF) 602; rifampin interaction (CR) 559; ventricular tachycardia (CTF) 953
Vidarabine, theophylline interaction (CTF) 68
Vincristine, hepatotoxicity (CTF) 228
VIP News (NC), Babington, Maude A., 696; Barbarash, Rick A., 616; Barber, Jacqueline R., 616; Berman, Alex, 160; Brundage, Richard C., 880; Burns, J. Michael, 80; Caldwell, R. Dewayne, 616; Davis, Sharon K., 616; Elenbaas, Robert M., 792; Goldberg, Leon I., 80; Higuchi, Takeru, 880; Jozefczyk, Kenneth G., 616; Knowles, Mark R., 412; Manoguerra, Anthony S., 80; Miller, Jane L., 880; Netter, Frank, 616; O'Neal, Welton, 616; Scarborough, John, 792; Stewart, Ronald B., 504; Wellman, Gregory S., 616; York, John, 504; Yost, Richard L., 880
Vishniavsky, N. (coauthor) see **Tartaglione, Teresa A.**, 459
Vitamin D, sodium fluoride, calcium gluconate, otospongiosis (CTF) 775
Vitamin E, mammary dysplasia (CTF) 491
Vlasses, Peter H. (author) Crossover Study of Bucindolol and Diuretic vs. Standard Triple Therapy in Moderate-to-Severe Essential Hypertension (ab) 454; (author) Pharm.D. Faculty in Colleges of Medicine (L) 948; (author) Pharm.D.: A Prolific Author (L) 844; (author) The Role of Beta-Blocking Agents Following Myocardial Infarction (TC) 581; (coauthor) see **Conner, Dale P.**, 453; (coauthor) see **Larijani, Ghassem E.**, 454; (coauthor) see **Pietruszka, Laura J.**, 31; (coauthor) see **Rocci, Mario L., Jr.**, 831
Von Hoff, D. (coauthor) see **Kuhn, John**, 457

W

Waas, R.J.M. (coauthor) see **Dirksen, M.S.C.**, 945
Wagner, Jon C. (coauthor) see **Sklar, Stephen J.**, 34
Walker, Scott E. (author) Bioavailability and Metabolism of Enteric-Coated Acetylsalicylic Acid: Intrasubject Variability (ab) 468; (author) Effect of Smoking and Food on Single-Dose Sustained-Release Theophylline Disposition (ab) 468
Wallace, R.B. (coauthor) see **Semla, T.P.**, 452
Wallemacq, Pierre E. (author) Accidental Massive IV Administration of Cyclosporine in Man (CR) 29
Waller, Elaine S. (coauthor) see **Britton, Mark L.**, 666; (coauthor) see **Sagraves, Rosalie**, 55; (coauthor) see **Talbert, Robert L.**, 448
Walshe, J.J. (coauthor) see **Morse, Gene D.**, 469
Wang, P. (coauthor) see **Bussey, Henry I.**, 458
Warda, Janet (author) Amphotericin B Nephrotoxicity (DIAS) 25
Warenius, H. (coauthor) see **Jackson, M.**, 841
Warfarin, concentration, effect of sucralfate (ab) 456; piroxicam interaction (CR) 556
Watson, William (author) book review, 601; (author) Development of a Monoclonal Anti-Digoxin Antibody Immunoassay (ab) 458; (coauthor) see **Bussey, Henry I.**, 458
Weber, Robert J. (author) The Intensive Care Unit Syndrome: Causes, Treatment, and Prevention (CC) 13
Weber, Stanley S. (author) book review, 69
Webster, W.B. (author) Stereospecific Protein Binding of Propranolol (ab) 463
Weinberger, Miles (coauthor) see **Milavetz, Gary**, 458; (coauthor) see **Vaughan, Leigh**, 452
Weiner, M. (coauthor) see **Vaughan, Leigh**, 452
Weiss, G. (coauthor) see **Schwartz, R.**, 457
Weitz, Raphael (coauthor) see **Shuper, Avinoam**, 924
Welch, Janet (coauthor) see **Cersosimo, Robert J.**, 118
Wellman, Gregory S., appointments at Medical University of South Carolina (NC) 616
Wells, Barbara G. (author) Factors Associated with the Elderly Falling in Intermediate Care Facilities (G) 142
Wermeling, Daniel P. (coauthor) see **Rapp, Robert P.**, 56
West, Dennis P. (author) book review, 323; (author) Improvement of Patient Compliance to Dapsone by use of a Continual Monitoring Program in an Outpatient Hansen's Disease Clinic (ab) 464
White, R.L. (author) The Pharmacokinetics of Cefuroxime and Cefamandole in Healthy Volunteers (ab) 460
White, R.M. (coauthor) see **Osathanondh, Rapin**, 445
Whitney, Harvey A.K., Jr. (author) An Official Journal for the American College of Clinical Pharmacy (E) 920
Wightkin, William T. (author) Objectivity in Drug Therapy (L) 55
Wilford, Colleen (coauthor) see **Marinier, Raymonde L.**, 40
Wilkins, Penny (author) Steroids in the Treatment of Croup (DIAS) 360
Williams, James (coauthor) see **Stewart, Clinton F.**, 451
Winship, M. Jay (coauthor) see **Rivey, Michael P.**, 908
Winslade, N. (coauthor) see **Walker, Scott E.**, 468
Winters, Cora B. (coauthor) see **Nahata, Milap C.**, 834
Wiser, Thomas H. (author) Comment: Antibiotics in Acute Exacerbations of COAD (L) 397
Wisman, Richard (coauthor) see **Ponte, Charles D.**, 479
Witte, Kenneth W. (author) Justification of Clinical Pharmacy Services on Cardiology Units (ab) 452; (coauthor) see **Hutchinson, Richard A.**, 655
Wojciechowski, Norbert J. (coauthor) see **Carter, Charles A.**, 812
Women, psychotropic drugs (RPR) 40
Wood, Charles A., Jr. (coauthor) see **Harrison, Sandra A.**, 747
Wood, George C. (coauthor) see **Straughn, Arthur B.**, 461
Wooding-Scott, R. (coauthor) see **Farringer, John A.**, 461
Worobec, Sophie M. (coauthor) see **West, Dennis P.**, 464
Wright, C. Eugene, III (author) The Influence of Age on the Pharmacokinetics of Tolazamide (ab) 458
Wright, G.J. (coauthor) see **Lehmann, Craig R.**, 460
Wright, Harry H. (coauthor) see **Batey, Sharyn R.**, 844

Y

Yacobi, Avraham (author) book review, 323, 773; (coauthor) see **DuKart, Gary**, 216
Yee, Gary C. (author) Correlation of Serum Cyclosporine Concentration to Renal Dysfunction in Marrow Transplant Recipients (ab) 445
Yen, Linda (author) Cimetidine-Induced Diarrhea (DIAS) 185
York, John, Student APhA National Patient Counseling Competiton award (NC) 504
Yost, Richard L. (author) Ceftazidime Review (FF) 509; (author) Pharmacokinetics of Cefotaxime and its Metabolite in Normal and Morbidly Obese Subjects (ab) 463; (editor) Antibiotic Cost-Containment in the Home Health Care Environment (S) 277; associate professor, College of Pharmacy, Medical University of South Carolina (NC) 880
Young A. Byron (coauthor) see **Bertch, Karen E.**, 561
Yuen, Geoffrey J. (author) Phenytoin Dosage Prediction in Children using Bayesian Forecasters (ab) 469

Z

Zarowitz, Barbara J.M. (author) Ultrafiltration Clearance of Aminoglycoside Antibiotics (ab) 459
Zeli, Michele (author) book review, 599
Zeller, Frederick P. (coauthor) see **Witte, Kenneth W.**, 452
Zelman, Lawrence (coauthor) see **Sargenti, Christine**, 380
Zinc oxide, leg ulcers (CTF) 324

INDEX ABBREVIATIONS

A:	Article
ab:	abstracts, ACCP Annual Meeting
ACCP:	American College of Clinical Pharmacy
CC:	Critical Care Therapeutics
CR:	Clinical Pharmacy Case Reports
CT:	Clinical Trials
CTF:	Current Therapeutic Findings
ctr:	center insert
DIAS:	Drug Information Analysis Service
DIR:	Drug Interactions and Reactions Update
DSP:	Drug Selection Perspectives
E:	Editorial
FF:	Formulary Forum
G:	Geriatrics and Gerontology
ibc:	inside back cover
ID:	Investigational Drug Information
ifc:	inside front cover
IR:	International Reports
L:	Letters
LA:	Literature Analysis
NC:	News and Comments
NDE:	New Drug Evaluations
O:	An Opinion
obc:	outside back cover
OT:	Oncology Therapeutics
PA:	Physical Assessment
RPR:	Research/Practice Reports
S:	Symposium
TC:	Therapeutic Controversies
TM:	Therapeutic Monitoring

ADVERTISERS

(see also main index terms: **Announcements; Fellowships and Residencies**
American Society of Hospital Pharmacists, International Pharmaceutical Abstracts, 12, 84, 169, 245
Beecham Laboratories, Ticar, 700, 796, 884
Bristol Laboratories, Cefadyl, 167, 339
Burroughs Wellcome Company, Wellcovorin, 70, 236, 336, 612, 618, 788
Drug Intelligence and Clinical Pharmacy, Index Plantarum Medicinalium, 301, 338, 492, 790, 880; Stethoscopic Heart Album, 20, 89, 175, 276, 402, 641, 811
Harvey Whitney Books, KINPAK, 589, 620, 702, 798, 886; Psychotropic Drug Handbook, ibc-Fe, 187, 244, 348, 487, 547, 694, 713, 817, 927; The Practice of Pharmacy, 83, 166, ibc-Ap, ibc-Je, ibc-J/A, ibc-Oc, ibc-De
Lederle Laboratories, Maxzide, insert between 72-73, 168-169, 340-341, 608-609, 688-689, 872-873; Pipracil, ifc-Ja, ifc-Fe, ifc-My, ifc-J/A, ifc-Se, ifc-No
Mosby & James Laboratories, Hemoccult, 240
Personnel Placement, 73, 154, 230, 326, 407, 493, 609, 689, 783, 872, 956; **Alaska**, Anchorage, Providence Hospital, 692; **Arkansas**, Little Rock, University of Arkansas for Medical Sciences, 495; **California**, Los Angeles, UCLA Medical Center, 875, San Francisco, University of California, 73, 155, 209, San Jose, Santa Clara Valley Medical Center, 326, Stockton, University of the Pacific, 155, 610, 958; **Canada**, British Columbia, Vancouver, The University of British Columbia, 623, Ontario, Toronto, University of Toronto, 73; **Florida**, Fort Myers, Fort Myers Community Hospital, 610, Gainesville, University of Florida, 155, 232, 691, Jacksonville, Saint Vincent's Medical Center, 495, 959, Miami Beach, Mt. Sinai Medical Center, 407, 691; **Idaho**, Pocatello, Idaho State University, 495, 873; **Illinois**, Chicago, The University of Illinois, 872, 873, 874; **Iowa**, Des Moines, Broadlawns Medical Center, 692, Iowa City, University of Iowa, 73, 783; **Japan**, Tokyo, International Education Services, 231; **Massachusetts**, Boston, Massachusetts College of Pharmacy and Allied Health Sciences, 691, Tufts University, 957, Framingham, Medical East Community Health Plan, 496; **Michigan**, Ann Arbor, University of Michigan, 407, Detroit, Detroit Receiving Hospital and University Health Center, 231, Wayne State University, 611, 784, 958, Midland, Midland Hospital Center, 784; **Minnesota**, Minneapolis, Data Med, Inc., 496, University of Minnesota, 230, 231, 407, Rochester, Rochester Methodist Hospital, 74, St. Paul, St. Paul-Ramsey Medical Center, 610; **Missouri**, Kansas City, University of Missouri-Kansas City, 689, St. Louis, St. Louis College of Pharmacy, 495; **Nebraska**, Omaha, Creighton University, 230; **New Jersey**, Piscataway, Rutgers—The State University, 154, 692, Secaucus, Advanced Therapeutics Communications, 692, Somerville, American Hoechst Corporation, 958; **New York**, Albany, Albany College of Pharmacy, 156, 874, 958, Jamaica, St. John's University, 231, New York, Memorial Sloan-Kettering Cancer Center, 232, 233, 408, 494, 609, 690, 876; **North Carolina**, Durham County General Hospital, 915, Greensboro, Moses H. Cone Memorial Hospital, 73, 785; **Ohio**, Columbus, The Ohio State University, 74, 872, 874, 957, 958, Toledo, The University of Toledo, 156; **Oregon**, Clackamas, Kaiser Permanente-Northwest Region, 623, 785, Portland, Oregon Health Sciences University, 407; **Pennsylvania**, Erie, Hamot Medical Center, 692, Philadelphia, Hospital of the University of Pennsylvania, 73; **Saudi Arabia**, Riyadh, King Faisal Specialist Hospital and Research Centre, 326, 493, 785, 959, King Saud University, 75, 156; **Texas**, Amarillo, High Plains Baptist Hospital, 874, 958, Austin, The University of Texas, 407, 496, 611, 784, 872, 958, Dallas, Parkland Memorial Hospital, 691, Houston, Texas Southern University, 326; **Utah**, Salt Lake City, University of Utah, 231; **Virginia**, Harrisonburg, Shenandoah Shared Hospital Services, Inc., 610; **Washington**, Spokane, Spokane VA Medical Center, 611; **West Virginia**, Morgantown, West Virginia University, 915, West Virginia University Medical Center, 873, 957; **Wyoming**, Evanston, Wyoming State Hospital, 784, 872, 958
Pfizer Pharmaceutic Inc., Vibramycin, 693
Roche Laboratories, Continuing Education Materials, 780; Research Grant Program, 342, 498
SmithKline Beckman Corporation, Ancef, 165

Statement of ownership, management, and monthly circulation of *Drug Intelligence and Clinical Pharmacy*, publication no. 126578. Owner: Drug Intelligence and Clinical Pharmacy, Inc. (a nonprofit corporation). Publisher, editor, and managing editor: Harvey A.K. Whitney, Jr. Headquarters of publisher and publication: 10123 Alliance Road, P.O. Box 42696, Cincinnati, OH 45242. Known bondholders, mortgagees, and other security holders: none. Average no. of copies each issue from November 84 to October 85 and no. copies of October 85: A. total no. copies printed (net press run) 10 975, 13 099; B. paid circulation (1) single copy sales 0, 0; (2) mail subscription 8598, 10 916; C. total paid circulation 8598, 10 916; D. free distribution 1995, 1198; E. total distribution (C + D) 10 593, 12 114; F. office use, left over, etc. 382, 985; G. total (E + F) 10 975, 13 099. No. of issues published annually: 12. Date of filing: 30 September 1985.